1 
PRP Study Protocol V5 October 2023   
STUDY PROTOCOL  
 
PARTNERS FOR PAIN & WELLBEING EQUITY:  
A RANDOMIZED TRIAL OF COMMUNITY SUPPORTED 
COMPLEMENTARY AND INTEGRATIVE HEALTH  
SELF -MANAGEMENT FOR BACK PAIN   
 
 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
 
Principal Investigators:  Roni Evans, DC, MS, PhD & Brent Leininger, DC, MS , PhD  
Integrative  Health  & Wellbeing  Research  Program   
Earl E. Bakken  Center  for Spi[INVESTIGATOR_25824]  & Healing  
C504  Mayo  Memorial  Building,  University  of Minnesota  
[ADDRESS_333518]  S.E. 
Minneapolis,  MN,  [LOCATION_003] [ZIP_CODE]  
 
 
Grant Number: 1R61AT012309  
 
Funded by: [CONTACT_272942]’s Helpi[INVESTIGATOR_272874] (HEAL) Initiative  
 
Version Number:  5  
 
October 23 2023  
 
Confidentiality Statement: This document is confidential communication. Acceptance of this 
document constitutes agreement by [CONTACT_1955][INVESTIGATOR_272875].   
 
 
 
 
 
 
 
2 
PRP Study Protocol V5 October 2023  PROTOCOL  REVISION HISTORY  
 
Protocol 
Version #  Revision 
Date  Summary of Changes  Protocol Section(s)  
2 May 2023  Updated non -key personnel: Removed Jennifer Walter  3. Study Roster  
2 May 2023  Clarified study is conducted in English and 
supplementary materials are available in Spanish for 
individuals with English as a second language  9.2 Inclusion Criteria  
2 May 2023  Added details about the use of TransportationPlus, a 
rideshare program that will be used to transport 
participants to study visits to  address a potential barrier 
to participation.  9.4.5 Retention Strategies  
9.4.6 Strategies for Addressing 
Barriers to Recruitment & 
Retention of Populations Who 
Experience Health Disparities  
2 May 2023  Changed minimum group size from 10 to 7  11.1 Intervention Overview  
2 May 2023  Updated screening activities and clarified the timing 
between randomization and the start of the group 
interventions is up to 28 days. Also clarified the timing 
for follow up assessments (Month 2 for the R61 and 
Months 2, 4, and 6 for the R33) is from the start of the 
group interventions.  13.2 Screening Assessments  
13.3 Intervention Sessions  
13.4 Follow up Assessments  
2 May 2023  Included video presentation of study and timing for 
when it would be sent to potential participants  16.1.2 Consent Procedures and 
Documentation  
3 July 2023  Added the following questionnaires: Perceived 
Discrimination in Healthcare  and an adapted version to 
assess Perceived Discrimination in the P4P Study.  
 13.1 Schedule of Assessments  
13.2.3 Baseline Two Screen  
14.2.3 Implementation & Disparity 
Mitigating Outcomes  
 
3 July 2023  Updated non -key personnel: Added Emma Ward, 
Shraddha Bika, Jake Kremer, and Erika Kennedy; 
removed Aditi Das.  3. Study Roster  
[ADDRESS_333519] 
2023  Updated sample size (n=30 -60) from (n=30 -40). 
Response to recruitment initiatives has gone very well. 
Study team wanted to provide additional opportunity 
for underserved participants to be included in the 
study. Funds and resources are in place for up to [ADDRESS_333520] 
2023  Removed Gaye Adams Massey from External Co -
Investigator Consultants (no access to participants or 
identified data).  3 Study Roster  
5 October 
2023  Added Carmen Robles, Ivette Izea -Martinez, Jamiela  
Taylor (no access to participants or identified data). 
Added section for former team members and listed past 
project personal: Kari Davis BA, Aditi Das MPH, and Gaye 
Adams Massey , JD. 
Updated credentials for project team  3 Study Roster  
 
  
3 
PRP Study Protocol V5 October 2023  TABLE OF CONTENTS  
 
1 Statement of Compliance  ................................ ................................ ................................ .......  9 
2 Investigator Signatures  ................................ ................................ ................................ .........  10 
3 Study Roster  ................................ ................................ ................................ ..........................  11 
4 Protocol Summary  ................................ ................................ ................................ ................  16 
4.1 Synopsis  ................................ ................................ ................................ ..........................  16 
4.2 Study Overview  ................................ ................................ ................................ ..............  18 
4.3 Participating Sites  ................................ ................................ ................................ ...........  19 
5 Introduction  ................................ ................................ ................................ ..........................  20 
5.1 Background ................................ ................................ ................................ .....................  20 
6 Study Objectives  ................................ ................................ ................................ ...................  23 
6.1 R61 Aims & Transition Milestones  ................................ ................................ .................  23 
6.2 R33 Aims  ................................ ................................ ................................ .........................  25 
7 Risk/Benefit Assessment  ................................ ................................ ................................ .......  25 
7.1 Overview of Risk/Benefit ................................ ................................ ................................  25 
7.2 Benefits ................................ ................................ ................................ ...........................  25 
7.2.1  Quality Improvement Activities (R61/R33)  ................................ .............................  26 
7.2.2  Randomized Pi[INVESTIGATOR_16116] (R61) & Randomized Trial (R33)  ................................ ...... 26 
7.3 Risks  ................................ ................................ ................................ ................................  26 
7.3.1  Quality Improvement Activities (R61, R33)  ................................ ............................  26 
7.3.2  Randomized Pi[INVESTIGATOR_16116] (R61) & Randomized Trial (R33)  ................................ ...... 26 
7.4 Risk Mitigation  ................................ ................................ ................................ ................  27 
8 Study Design ................................ ................................ ................................ ..........................  28 
8.1 Overall Design  ................................ ................................ ................................ ................  28 
8.2 Study Rationale  ................................ ................................ ................................ ..............  28 
8.3 Underlying Models & Frameworks  ................................ ................................ ................  29 
9 Study Population  ................................ ................................ ................................ ...................  30 
9.1 Study Population Definitions ................................ ................................ ..........................  30 
9.2 Inclusion Criteria  ................................ ................................ ................................ ............  30 
9.3 Exclusion Criteria  ................................ ................................ ................................ ............  31 
9.4 Recruitment & Retention  ................................ ................................ ...............................  32 
4 
PRP Study Protocol V5 October 2023  9.4.1  Recruitment Process  ................................ ................................ ...............................  32 
9.4.2  Source & Identification of Potential Participants  ................................ ...................  32 
9.4.3  Recruitment Materials  ................................ ................................ ............................  33 
9.4.4  Payment  ................................ ................................ ................................ ..................  33 
9.4.5  Retention Strategies  ................................ ................................ ...............................  33 
9.4.6  Strategies For Adressing Barriers to Recruitment & Retention of Populations who 
Experience Health Disparities (PEHD)  ................................ ................................ ...................  34 
10 Enrollment Procedures  ................................ ................................ ................................ ...... 35 
10.1  Number of Study Participants  ................................ ................................ ....................  35 
10.2  Screening & Enrollment  ................................ ................................ ..............................  35 
10.3  Randomization & Blinding  ................................ ................................ ..........................  35 
11 Interventions  ................................ ................................ ................................ ......................  35 
11.1  Intervention Overview  ................................ ................................ ................................  35 
11.2  Experimental Intervention (Partners4Pain)  ................................ ...............................  36 
11.3  Control Intervention (Keys to Wellbeing)  ................................ ................................ ... 37 
11.4  Intervention Fidelity  ................................ ................................ ................................ ... 37 
11.5  Intervention Adherence  ................................ ................................ .............................  37 
11.6  Concomitant Therapy  ................................ ................................ ................................ . 38 
11.7  Rescue Therapy ................................ ................................ ................................ ...........  38 
12 Intervention Discontinuation & Participant Withdrawal  ................................ ...................  [ADDRESS_333521] to Follow -up ................................ ................................ ................................ ........  39 
13 Study Assessments & Procedures  ................................ ................................ ......................  40 
13.1  Schedule of Assessments ................................ ................................ ............................  40 
13.2  Screening Assessments  ................................ ................................ ...............................  41 
13.2.1  Initial Screen  ................................ ................................ ................................ ........  41 
13.2.2  Baseline One Screen  ................................ ................................ ............................  41 
13.2.3  Baseline Two Screen ................................ ................................ ............................  41 
13.3  Intervention Sessions  ................................ ................................ ................................ . 42 
13.4  Follow -up Assessments  ................................ ................................ ..............................  42 
13.5  Adverse Events & Serious Adverse Events  ................................ ................................ . 42 
13.5.1  Definition of Adverse Events  ................................ ................................ ...............  42 
5 
PRP Study Protocol V5 October 2023  13.5.2  Definition of Serious Adverse Events  ................................ ................................ .. 42 
13.5.3  Classification of an Adverse Event  ................................ ................................ ...... 43 
13.5.4  Relationship to Study Procedures  ................................ ................................ .......  43 
13.5.5  Expectedness  ................................ ................................ ................................ .......  43 
13.5.6  Time Period & Frequency for Event Assessment & Follow -up ...........................  44 
13.5.7  Adverse Event & Serious Adverse Event Reporting  ................................ ............  [ADDRESS_333522]  ................................ ................................ ....................  45 
13.5.9  Reporting of Pregnancy  ................................ ................................ .......................  45 
13.6  Unanticipated Problems  ................................ ................................ .............................  45 
13.6.1  Unanticipated Problems Reporting  ................................ ................................ ..... 46 
14 Outcomes  ................................ ................................ ................................ ...........................  46 
14.1  R61 Outcomes  ................................ ................................ ................................ ............  46 
14.1.1  VIEWS AND OPI[INVESTIGATOR_272876]  ................................ ................................ .........................  47 
14.1.2  Feasibility Outcomes  ................................ ................................ ...........................  48 
14.2  R33 Randomized Hybrid Effectiveness -Implementation Trial  ................................ ... 49 
14.2.1  Primary Effectiveness Outcome  ................................ ................................ ..........  49 
14.2.2  Secondary Effectiveness Outcomes  ................................ ................................ .... 50 
14.2.3  Implementation & Disparity Mitigating Outcomes  ................................ .............  51 
15 Statistical Considerations  ................................ ................................ ................................ ... 51 
15.1  Hypotheses  ................................ ................................ ................................ .................  52 
15.2  Sample Size  ................................ ................................ ................................ .................  52 
15.2.1  R61 Randomized Pi[INVESTIGATOR_16116]  ................................ ................................ ...............  52 
15.2.2  R33 Randomized Hybrid Effectiveness -Implementation Trial  ............................  52 
15.3  Populations for Analyses & General Approach (R33)  ................................ .................  53 
15.4  Data Analyses  ................................ ................................ ................................ .............  53 
15.4.1  R61 Phase  ................................ ................................ ................................ ............  53 
15.4.2  R33 Randomized Hybrid Effectiveness -Implementation Trial  ............................  54 
16 Regulatory, Ethical, & Study Oversight  ................................ ................................ ..............  55 
16.1  Informed Consent  ................................ ................................ ................................ .......  55 
16.1.1  Consent & Other Informational Documents  ................................ .......................  55 
16.1.2  Consent Procedures & Documentation  ................................ ..............................  56 
16.2  Study Discontinuation & Closure  ................................ ................................ ................  57 
16.3  Confidentiality & Privacy  ................................ ................................ ............................  58 
6 
PRP Study Protocol V5 October 2023  16.4  Key Roles & Study Governance  ................................ ................................ ..................  59 
16.5  Safety Oversight ................................ ................................ ................................ ..........  62 
16.6  Clinical Monitoring  ................................ ................................ ................................ ..... 62 
16.7  Quality Assurance & Quality Control  ................................ ................................ ..........  63 
16.8  Data Handling & Record Keepi[INVESTIGATOR_007]  ................................ ................................ ...............  63 
16.8.1  Data Collection & Management Responsibilities  ................................ ................  63 
16.8.2  Study Records Retention  ................................ ................................ .....................  64 
16.9  Protocol Deviations  ................................ ................................ ................................ .... 64 
16.10  Publication & Data Sharing Policy  ................................ ................................ ..............  [ADDRESS_333523]  ................................ ................................ .......  29 
Table 4. Study Population Definitions and Nature of Participation  ................................ .............  30 
Table 5. TIDieR Intervention Elements Common to Both Groups  ................................ ................  36 
Table 6. Schedule of Assessments for Study Participants** (R61 Randomized Pi[INVESTIGATOR_272877] 
R33 Randomized Trial)  ................................ ................................ ................................ ..................  40 
Table 7. Relationship of Adverse Events to Study Procedures  ................................ .....................  43 
Table 8. Reporting for Adverse events, Serious adverse events, and Other events  ....................  44 
Table 9.  Schedule of Quality Improvement Data Collection ................................ ........................  47 
Table 10. Key Roles and Study Governance  ................................ ................................ ..................  60 
 
  
7 
PRP Study Protocol V5 October 2023  ABBREVIATIONS/DEFINITIONS  
ADL   Activities of Daily Living   
AE    Adverse Event  
APEASE   Affordability, Practicality, Effectiveness, Adaptability, Safety, Equity  
BL    Baseline  
BP    Back pain  conditions including back or neck pain  
BP-PEHD     Back pain from populations that experience health disparities  
BPS    Biophysical, psychological and social  
CC   Creative commons  
CIH    Complementary and Integrative Healthcare  
Co-I    Co-Investigator  
CoC   Certificate of Confidentiality  
COI    Conflict of Interest  
COM -B   Capability, Opportunity, Motivation - Behavior  
ConNECT  Integrating CON text; Fostering a Norm of Inclusion; Ensuring Equitable Diffusion 
of Innovations; Harnessing Communication Technology; Prioritizing Specialized 
Training  
CRF      Code of Federal R egulations  
CRF    Case report form  
CV   Curriculum Vitae  
DC      Doctor of Chiropractic  
DSMP    Data Safety and Monitoring Plan  
ETHOS    Ethical Oversight Submission System  
FFR    Federal Financial Report  
GAD    Generalized Anxiety Disorder  
GCP      Good Clinical Practice  
HEAL    Helpi[INVESTIGATOR_272878] -Mental Status Examination  
MOP    Manual of Operations  
MS      Master of Science  
NCCIH    National Center for Complementary and Integrative Health  
NCT   National Clinical Trial  
NIH       National Institutes of Health  
NP    Neck Pain  
8 
PRP Study Protocol V5 October 2023  OHRP    Office for Human Research Protections  
OIC    Office of Institutional Compliance  
P&A    Professional & Administrative  
PEG    Pain, Enjoyment of Life and General Activity  
PEHD    Populations Experiencing Health Disparities  
PGIC    Patient Global Impression of Change  
PhD      Doctor of Philosophy  
PHQ -2   Patient Health Questionnaire -2 
PI    [INVESTIGATOR_272879] -Reported Outcome Measurement Information System  
RE-AIM   Reach, Effectiveness, Adoption, Implementation, Maintenance  
REDCap   Research Electronic Data Capture  
REPA     Report of External Professional Activities  
RNI    Report of New Information  
SAE    Serious Adverse Event  
SARP    Study Accrual and Retention Plan  
SPH   School of Public Health  
SRQ   Self-Report Questionnaire  
TAPS    Tobacco, Alcohol, Prescription medications and other susbtances  
TIDieR    Template for implementation for intervention description and replication   
UMN    University of Minnesota  
UPI[INVESTIGATOR_272880] J. Jones Urban Research and Outreach -Engagement Center  
[LOCATION_003]   [LOCATION_002] of America  
US      [LOCATION_002]  
VA   Veterans Administration  
YMCA    Young Men’s Christian Association  
YWCA    Young Women’s Christian Association  
  
9 
PRP Study Protocol V5 October 2023  1 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Council on Harmonization Good Clinical 
Practice (ICH GCP) and the following:  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 
CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
 
National Institutes of Health (NIH) -funded investigators and clinical trial site staff who are responsible 
for the conduct, management, or oversight of NIH -funded clinical trials have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form(s) 
must be obtained before any participant is consented. A ny amendment to the protocol will require 
review and approval by [CONTACT_3484]. All changes to the 
consent form(s) will be IRB approved; a determination will be made regarding whether a new consent 
needs to be obta ined from participants who provided consent, using a previously approved consent 
form.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10 
PRP Study Protocol V5 October 2023  2 INVESTIGATOR SIGNATURES   
 
The signatures below constitutes  the approval of this protocol and provides the necessary assurances 
that this study will be conducted according to all stipulations of the protocol, including all statements 
regarding confidentiality, and according to local legal and regulatory requiremen ts and applicable US 
federal regulations and ICH guidelines, as described in the Statement of Compliance  above.  
 
 
 
 
Principal Investigator [INVESTIGATOR_7496]:                                                              Date  10/23/2023  
Name:  [CONTACT_273000], MS, PhD  
Title : Director and Associate [CONTACT_199819]:   Integrative Health & Wellbeing Research Program, Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & 
Healing, University of Minnesota  
Telephone: [PHONE_5675]  
Email: [EMAIL_5305]  
 
Principal Investigator [INVESTIGATOR_7496]:                                                  Date  10/23/2023  
Name:  [CONTACT_273001], MS, PhD  
Title : Assistant [CONTACT_199819]:   Integrative Health & Wellbeing Research Program, Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & 
Healing, University of Minnesota  
Telephone: [PHONE_5675]  
Email: [EMAIL_5306]  
 
 
 
 
 
 
 
 
  

11 
PRP Study Protocol V5 October 2023  3 STUDY ROSTER   
 
KEY PERSONNEL  
 
University of Minnesota  Investigators  
 
Roni Evans , DC, MS, PhD  
Co-Principal Investigator  
[INVESTIGATOR_272881] E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333524], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5305]  
 
Brent Leininger , DC, MS , PhD  
Co-Principal Investigator  
[INVESTIGATOR_272881] E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333525], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5306]  
 
Robin Austin , MS, DC, DNP, PhD  
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333526], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5307]  
 
Gert Bronfort, DC, PhD  
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333527], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5308]  
 
Alex Haley, JD, MBA  
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333528], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5309]  
 
Linda Hanson, DC, MS  
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333529], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5310]  
 
12 
PRP Study Protocol V5 October 2023  Douglas Kennedy, MA, PhD 
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333530], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5311]  
 
Craig Schulz, DC, MS  
Co-Investigator  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333531], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5312]  
 
Julian Wolfson , PhD  
Co-Investigator  
Data Collection/Management  
University of Minnesota, School of Public Health  
[ADDRESS_333532] SE, Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5313]  
 
Diana Burgess, PhD  
Co-Investigator  
University of Minnesota, Department of Medicine  
[ADDRESS_333533], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5314]  
& 
US Department of Veterans Affairs, Center for Care Delivery and Outcomes Research  
2E-[ADDRESS_333534], Minneapolis MN [ZIP_CODE]  
Email: [EMAIL_5315]  and  
 
External Co -Investigator Consultants*  
*No access to study data or participants  
 
Eric Roseen , DC, MSc  
Co-Investigator  Consultant  
[LOCATION_011] University, School of Medicine  
[ADDRESS_333535], Room 1020, [LOCATION_011] MA [ZIP_CODE]  
Email: [EMAIL_5316]  
 
Hedy Lemar Walls , MBA, EDd  
Co-Investigator  Consultant  
YMCA of the North  
651 Nicollet Mall, Street2: Suite 500, Minneapolis MN [ZIP_CODE]  
Email: [EMAIL_5317]  
 
NON -KEY PERSONNEL  
Research Staff – University of Minnesota  
13 
PRP Study Protocol V5 October 2023  Oliver Ang, PT, MCISc , DSc  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333536], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5318]  
 
Shraddha Bika, PT  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333537], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5319]  
 
John Jodzio, BA  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333538], Minneapolis, MN [ZIP_CODE]  
Phone: (612) 301 -9006  
Email: [EMAIL_5320]  
 
Erika Kennedy , BA 
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333539], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5321]  
 
Jake Kremer, DPT  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333540], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5322]  
 
Amy McGarness, BA  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333541], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5323]  
 
Don Thorpe, DC , MS  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333542], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5324]  
 
Blong Vang, DC  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333543], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5325]   
[ADDRESS_333544], BS  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333545], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5326]  
 
Lynn Winkel, DC  
Earl E. Bakken Center for Spi[INVESTIGATOR_25824] & Healing  
University of Minnesota, Mayo Memorial Building C504  
[ADDRESS_333546], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5327]  
 
Consultants * 
*No access to study data or participants  
 
Merrie Benasutti  BA, MSEd  
University of Minnesota, Office for Public Engagement  
[ADDRESS_333547]. SE, Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5328]  
 
Ronda Chakolis  PharmD, MPH  
MN State Board of Pharmacy  
Prime Therapeutics  
Email: [EMAIL_5329]  
 
Clarence Jones  M.Ed, CPH, CHW, CPE  
Hue-MAN Partnership  
Email: [EMAIL_5330]  
 
 
Robin Hedrick  MA, NBC -HWC  
YMCA of the North  
651 Nicollet Mall, Street2: Suite 500, Minneapolis MN [ZIP_CODE]  
Email: [EMAIL_5331]  
 
Nawal Hirsi  BS 
Fairview Health Services, Community Advancement, Community Program & Initiatives  
Email: [EMAIL_5332]  
 
Ivette Izea -Martinez   
YWCA of St.  Paul  
Email: [EMAIL_5333]  
 
Mallory Mahaffey  MPH, LADC  
VA Minnesota  
Email: [EMAIL_5334]  
 
[ADDRESS_333548], Bloomington, MN [ZIP_CODE]  
Email: [EMAIL_5335]  
 
Carmen Robles  
[ADDRESS_333549] Paul, MN [ZIP_CODE]  
Email: [EMAIL_5336]  
 
Sam Simmons  LADC  
Samuel Simmons Consulting  
[ADDRESS_333550] S, [PO_BOX], Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5337]  
 
Jamiela Taylor , BA 
NorthPoint Health & Wellness Center  
[ADDRESS_333551] North, Suite 5300 Minneapolis, MN [ZIP_CODE]  
Email: [EMAIL_5338]  
 
Bruce Yang  BS 
YMCA of the North  
651 Nicollet Mall, Street2: Suite 500, Minneapolis MN [ZIP_CODE]  
Email: [EMAIL_5339]  
 
Makeda Zulu  MPA  
University of Minnesota  
Robert J. Jones Urban Research and Outreach -Engagement Center  
Email: [EMAIL_5340]  
 
 
Past Project Personal  
 
Aditi Das , MPH  
University of Minnesota  
Email: [EMAIL_5341]  
 
Kari Davis  
Make a Wish Minnesota  
Email: [EMAIL_5342]  
 
Gaye Adams Massey, JD  
Co-Investigator Consultant  
YMCA St. Paul  
[ADDRESS_333552]. Paul MN [ZIP_CODE]  
Email: [EMAIL_5343]  
  
16 
PRP Study Protocol V5 October 2023   
4 PROTOCOL SUMMARY  
 
4.1 SYNOPSIS  
 
The following provides a synopsis for the R61 (Phase I)  of the project.  
 
Title  Phase I (R61):  Partners for Pain & Wellbeing Equity: A Randomized Trial of Community 
Supported Complementary and Integrative Health Self -Management for Back Pain  
Grant Number  1R61AT012309  
Study Description  The focus of the R61 project is on developi[INVESTIGATOR_272882] -based 
programs for the self -management of back  or neck  pain for individuals from 
populations that experience health disparities  (BP-PEHD) . We will use a community -
engaged research approach to conduct quality improvement activities that involves 
gathering feedback from multiple stakeholders to inform development of the study 
intervention s and materials  which will be followed by a randomized pi[INVESTIGATOR_14737] 30 
to 60 participants to evaluate  feasibility .  
Objectives/Aims  Aim 1:  We will use mixed methods data collection from multiple levels of stakeholders 
to assess barriers and facilitators to participating in back pain self -management, and 
community supported programs.  
Aim 2. Based on information gathered in Aim 1, we will perform participatory 
intervention mappi[INVESTIGATOR_272883] -develop a community supported CIH self -management 
intervention program (and control) for BP -PEHD.  
Aim 3. We will conduct a feasibility study (n= 30 to 60 ) to assess essential scientific and 
feasibility milestones including:  
a) Finalizing and securing agreements, and regulatory approvals (IRB, NCCIH, 
IMC) for all required protocols and plans (e.g., clinical protocol, Data Safety 
and Monitoring Plan, Study Accrual and Retention Plan, etc.)  
b) Recruiting and enrolling individuals with BP -PEHD and measuring recruitment 
rates, enrollment rates  
c) Delivering experimental and control interventions and measuring 
intervention adherence and fidelity rates  
d) Data collection by [CONTACT_272943]  
e) Stakeholder views of barriers and facilitators to the above, including 
affordability, practicality, effectiveness, acceptability, safety, and equity and 
other factors that could affect the future full scale trial’s success   
Endpoints  Aim 1 : Needs and perspectives for addressing barriers and facilitators to back pain 
management and participation in community supported CIH programs  
 
Aim 2:  Reactions and opi[INVESTIGATOR_272884] 1 findings and planned resources and 
approaches for the CIH self -management program and feasibility study  
 
Aim 3: Recruitment feasibility, enrollment feasibility, intervention acceptability and 
credibility, intervention fidelity, and data collection feasibility  
Study 
Populations  Aims 1 -3: Community Stakeholders defined as Community Partner Organization 
leadership members; Community Facilitators; and other Community Members for 
whom BP -PEHD is relevant   
 
17 
PRP Study Protocol V5 October 2023  Aim 3: 30 to 60 adults with chronic neck or back pain from populations that 
experience health disparities due to race/ethnicity or socioeconomic status  
Phase /Design  Mixed methods quality improvement (Aims 1, 2) leading to randomized pi[INVESTIGATOR_799] 
(Aim 3)  
Sites/Facilities  University of Minnesota; Community Partners include the YMCA of the North and 
YWCA St. Paul  
Study 
Interventions 
(experimental, 
control)  Both intervention programs include nine, 90 -minute group sessions that occur weekly.  
Experimental: Partners4Pain is a self -management program of evidence based 
complementary and integrative health approaches for pain including pain education, 
mindfulness, cognitive behavioral approaches, and neck/back specific exercises.  
 
Active Control: Keys to Wellbeing is a general health and wellbeing education program 
addressing topi[INVESTIGATOR_272885], finding meaning and purpose, 
addressing mental health, and keepi[INVESTIGATOR_272886]. The program was designed to 
control for time, att ention, and many other key contextual factors (e.g., program 
format, materials).  
Duration  Planning, preparation phase (Aims 1, 2):  Nine months  
Randomized pi[INVESTIGATOR_799] (Aim 3) : One year  
Participant 
Duration  Randomized pi[INVESTIGATOR_799]: Three months  
 
The following provides a synopsis for the future R33 (Phase II)  of the project.   
 
Title  Phase II (R33): Partners for Pain & Wellbeing Equity: A Randomized Trial of 
Community Supported Complementary and Integrative Health Self -Management for 
Back Pain  
Grant Number  TBD 
Study Description  The R33 project focuses on assessing the effectiveness of a community -based back or 
neck pain self-management program, Partners4Pain, relative to an active control for 
improving important outcomes impacted by [CONTACT_229721] (Aim 1), and the impact of 
health disparity factors (Aim 2). The project also focuses on gathering feedback as 
part of quality improvement activ ities to gain a better understanding of factors 
(including those that might mitigate disparities) that could affect the long -term 
implementation o f the community -based self -management programs (Aim 3).  
Objectives/Aims  Aim 1:  To assess the relative effectiveness of Partners4Pain versus Keys to Wellbeing 
in terms of:  
a) Primary effectiveness outcomes of pain intensity and interference over 6 months 
using bi -monthly assessments  
b) Secondary effectiveness outcomes of pain impact, self -efficacy and other HEAL 
outcomes  
 
Aim 2: To assess the impact of health disparity factors on the effectiveness of 
Partners4Pain for primary and secondary outcomes through subgroup analyses which 
account for potential complexities between disparity factors  
 
Aim 3: To describe important disparity mitigating and implementation related 
measures that can impact and inform sustained translation of the program with 
community partner organizations  
Endpoints  Aims 1 -2: Pain intensity and interference; pain impact; self -efficacy; life satisfaction; 
physical functioning; pain catastrophizing; interoceptive awareness; satisfaction; 
18 
PRP Study Protocol V5 October 2023  improvement; medication use; participation in social roles; healthcare use; CIH self -
management; sleep; depression; anxiety; substance use; adverse events  
 
Aim 3: Views on barriers/facilitators to participation, effectiveness, adoption, 
maintenance/sustainability, resource needs; Views on affordability, practicality, 
effectiveness, acceptability, safety, and equity of educational programs; Ability of 
programs to mee t capability, opportunity, and motivational related needs; Views on 
inclusion and cultural sensitivity; Views on the community -researcher relationship; 
Views on alignment with organizational mission and business models   
Study Populations  Aims 1 -3: 376 adults with chronic neck or back pain from populations that experience 
health disparities due to race/ethnicity or socioeconomic status  
 
Aim 3: Community Stakeholders defined as Community Partner Organization 
leadership members; Community Facilitators; and other Community Members for 
whom BP -PEHD is relevant  
Phase /Design  Phase II randomized hybrid effectiveness implementation trial using individual level 
randomization and group treatments (Aims 1, 2); quality improvement activities to 
gather and account  for stakeholder feedback (Aim 3).  
Sites/Facilities  University of Minnesota; Community Partners include the YMCA of the North and 
YWCA St. Paul  
Study 
Interventions 
(experimental, 
control)  Both intervention programs include nine, 90 -minute group sessions that occur 
weekly.  
Experimental: Partners4Pain is a self -management program of evidence based 
complementary and integrative health approaches for pain including pain education, 
mindfulness, cognitive behavioral approaches, and neck/back specific exercises.  
 
Active Control: Keys to Wellbeing is a general health and wellbeing education 
program addressing topi[INVESTIGATOR_272885], finding meaning and 
purpose, addressing mental health, and keepi[INVESTIGATOR_272886]. The program was 
designed to control for time, att ention, and other key contextual factors (e.g., 
program format, materials).  
Duration  Three years  
Participant 
Duration  Seven months  
 
 
4.[ADDRESS_333553] (R61/R33) supported through the National Institutes of 
Health’s Helpi[INVESTIGATOR_200608] -term (HEAL) Initiative.  The project is summarized below and in 
Figure 1.  
 
R61 Overview. The R61 Phase focuses on planning and preparation related ‘quality improvement 
activities’  (R61 Aims 1 -2) that will assess community stakeholder needs and optimize study interventions 
and appr oaches. A randomized pi[INVESTIGATOR_799]  (R61 Aim 3)  will evaluate feasibility  and provide another 
opportunity for ‘quality improvement’ activities and provide refinements in preparation for the R33 . The 
interventions are Partners4Pain (experimental), comprised of evidence based Complementary and 
Integrative Health ( CIH) modalities (e.g., pain education, mindfulness, cognitive behavioral approaches, 
exercises and physical activity) and an active control, Keys to Wellbeing. Both programs will leverage 
19 
PRP Study Protocol V5 October 2023  assets  (e.g. , content videos, workbooks, etc.) developed and successfully applied by [CONTACT_272944]; these will be used as a starting point to develop and optimize the programs for 
individuals with BP -PEHD.1-[ADDRESS_333554] of weekly 90 -minute group sessions for 
9 weeks that will be offered in -person and via videoconference depending on community partner 
organization and participant needs.  
 
R33 Overview. The R33 Phase includes a randomized hybrid effectiveness implementation trial (Aims 1 
and 2) to evaluate the effectiveness of the Partners4Pain intervention compared to the Key to Wellbeing 
active control intervention and the impact on health disparities r elated to pain management. The R33 
will also engage study participants and community stakeholders in ‘quality improvement activities’ (R33 
Aim 3) that assess their views of barriers and facilitators to long -term implementation of the 
Partners4Pain intervention in community -based settings , including those that may help mitigate 
disparities.  
 
 
 
4.3 PARTICIPATING SITES  
 
University of Minnesota Research Sites  
The University of Minnesota  Twin Cities  serves as the primary research site and will assume the 
following responsibilities:  
• Designing and developi[INVESTIGATOR_116081], manual of operations, informed consent and case report 
forms  
• Collecting and maintaining critical regulatory documents from affiliated investigators, e.g., 
resume/CV, certification of completion of training, signed COI disclosure forms, delegation of 
authority logs  

20 
PRP Study Protocol V5 October 2023  • Storing and/or managing data, performing data analysis, and data monitoring activities  
• Ensuring informed consent is obtained and documented from each subject in compliance with 
federal regulations  
• Recruiting, screening, and enrolling participants  
• Delivering study interventions  
• Protecting participants’ rights  
• Providing study specific training to research personnel  
• Developi[INVESTIGATOR_272887]  
• Monitoring compliance with protocol and tracking deviations from the study protocol  
• Ensuring the correct versions of the protocol and consent documents are used  
• Tracking, reporting, and maintaining documentation of all serious adverse events and 
unanticipated problems and disseminating the information to appropriate oversight boards  
• Providing periodic updates to affiliated investigators on subject enrollment, general study 
progress, and relevant scientific advances  
• Developi[INVESTIGATOR_272888], including data entry, error 
identification, and correction  
• AE monitoring and reporting  
• Implementing and monitoring quality control procedures  
• Generating and disseminating reports (e.g., enrollment, AEs, participant status, site 
performance, quality control)  
• Comply with necessary protocols and maintain consistency with the HEAL Initiatives Public 
Access and Data Sharing Policy  
• Maintaining documentation of IRB approvals and correspondence and communicating study 
status changes  
 
 
Participating University of Minnesota  Sites for the R61 are:  
Robert J. Jones Urban Research and Outreach -Engagement Center  
[ADDRESS_333555] , Minneapolis, MN [ZIP_CODE]  
Phone: 612-626-UROC (8762)  
Website: https://uroc.umn.edu/  
 
Community Partner Organization Sites: Leaders from the YMCA of the North, the YWCA St. Paul , and 
the Hue -MAN Partnership serve as consultants on this project. Their role is limited to sharing views and 
opi[INVESTIGATOR_272889], 
as well as disseminating information abou t the project through their routine communication channels. 
Leaders from Community Partner Organizations will facilitate the use of space  at their affiliated 
locatio ns for the University of Minnesota research staff to conduct research procedures (e.g., screening, 
intervention sessions). None of the Community Partners  (including their employees)  will take part in 
study activities involving human subjects nor will they have access to study data.  
[ADDRESS_333556].  Back pain (BP) conditions, including low back and neck pain, are among 
the most common and disabling chronic pain disorders in the U.S.11-14 and a leading cause of disab ility 
worldwide.15,16 An estimated 40 -80% of adults experience low back pain (LBP) or neck pain (NP), and 
almost one third of all Americans experience chronic NP or LBP at some point in their lives.11,[ADDRESS_333557] common reason for seeking care in the healthcare system21,22 and the U.S. spends more on BP 
than any other condition. In 2016, roughly 10% of healthcare expenditures ($134.5 billion) were devoted 
to the care of B P.[ADDRESS_333558] health conditions, has become widely recognized as more than a 
physical phenomenon; it is a complex condition influenced by [CONTACT_272945], psychological, 
and social (BPS) factors.24,25  
 
Population.  This study focuses on individuals with back pain from populations who experience health 
disparities (BP -PEHD) . Overall, there has been relatively little research examining BP -PEHD. While BP 
prevalence rates are similar between White and Black Americans, Black Americans are more negatively 
impacted with  higher severity and disability.26 
 
Current Back Pain Management.  While BP has become widely recognized as a biophysical, psychological  
and social condition, current BP management is still mainly biophysically oriented and the majority of 
cases remain poorly treated27,28 with a heavy emphasis on symptom management29,30 that fails to 
address sufferers’ needs.24,[ADDRESS_333559] on patient 
outcomes.32-35 Of particular concern is the overreliance on opi[INVESTIGATOR_2438], which are used by [CONTACT_159641] 30% 
of chronic LBP patients and 15% of all NP patients.36,[ADDRESS_333560] lower educational attainment, income, insurance 
coverage and self -reported health, are less likely to use complementary and integrative health (CIH) 
approaches, for which th ere is a growing evidence base.45 
 
Socioeconomic Factors and Health Disparities.  The relationships between socioeconomic factors and 
health disparities in the [LOCATION_002] are complex due to long -standing institutional discrimination and 
structural racism.46,47 There is evidence that socioeconomic  factors (e.g. , income, employment status, 
home ownership) are associated with greater likelihood of chronic pain and poorer outcomes.48-[ADDRESS_333561] on BP.54 Drawing from the larger pain 
field, poor quality relationships and social stressors (e.g. , due to racism, ostracism, injustice, invalidation, 
isolation, etc.) also contribute to poor outcomes.55,[ADDRESS_333562], it is 
imperative that social contexts are more intentionally considered and taken into account in the research 
process.  
 
Improved Pain Management . To reduce the burden of BP, individuals require greater access to evidence 
based care that addresses their biopsychosocial needs.57 There has been a growing recognition that BP, 
22 
PRP Study Protocol V5 October 2023  much like ot her chronic health conditions, requires ongoing attention to lifestyle factors and 
engagement in effective self-management.30,38 While patients recognize the need for self -management 
strategies, they often need support and validation to initiate and maintain optimal self -care.58,59 This 
isn’t surprising given that BP is frequently associated with psychological risk factors  including poor 
cognitive and emotional copi[INVESTIGATOR_4262], depression, catastrophizing, and fear avoidance beliefs, 
which can make self -management difficult.54,[ADDRESS_333563] modalities aimed at promoting active involveme nt in managing one’s condition.38,[ADDRESS_333564] that it is encountered throughout the lifespan, pain self -
management  can be viewed as a foundational behavioral skill that all could benefit from.  Commonly, 
self-management approaches help individuals learn and adopt a set of healthy behaviors (e.g., activity 
versus inactivity, socialization versus isolation, non -drug symptom management versus substance 
reliance). For BP, there is a range of CIH self -management modalities  including psychological strategie s 
(e.g. , behavioral or cognitive); mind -body approaches (including relaxation, meditation or guided 
imagery); physical activity (e.g. , general and rehabilitative exercise, yoga, tai chi); lifestyle advice (e.g. , 
for sleep, daily activities, social support); and pain education (e.g. , pain theories, progn osis, and pain 
management tips).39,45 Importantly, there is research evidence to support all of these CIH self -
management strategies for BP  (see Table 1). 
 
Table 1. CIH Self -Management Strategies for Back Pain  
Strategy  Evidence of effectiveness  
Pain education  Small effects on pain and function61,62 
Cognitive behavioral/copi[INVESTIGATOR_4262] 
(including progressive muscle relaxation and 
guided imagery)  Small effects on pain and function63 
Mindfulness based interventions  Small effects on pain, small to no effect on function63-65 
Exercise (back specific and general)  Moderate effects on pain, small effects on function63,66 
 
Whole Person CIH Self -Management.  There has been a growing number of multi -modality CIH self -
management programs that address pain from a whole person perspective (e.g. , taking into account BPS 
factors).67-[ADDRESS_333565] in and need for such an approach (R33AT00911, R34AT011209 -01S1 ). One of  the most studied 
existing pain self -management programs is the widely adopted Stanford Program which addresses pain 
from a more holistic perspective. It is comprised of lay person -led sessions including pain education, 
effective communication, mind -body a pproaches (e.g., relaxation), and general exercise for strength, 
flexibility , etc.[ADDRESS_333566] however, and the research 
is limited  by [CONTACT_272946]’  specific BP related 
needs with appropriate program elements; further , there has been a lack of consideration of key issues 
which may contribute to health disparities such as affordability, practicality, acceptability, safety, and 
equity.38,67,71,[ADDRESS_333567] demonstrated promise in having lay facilitators 
implement standardized group programs in community -based settings, including YMCAs.83 Recent work 
by [CONTACT_272947] -management programs in person 
or via telehealth (e.g., videoconferencing) with staff facilitators in YMCA and non -clinical VA settings 
(R33AT00911, NH170001). There  is still much work to be done however, including greater community 
stakeholder involvement - earlier, more frequently, and more collaboratively - throughout the research 
process,[ADDRESS_333568] long -term objective is to bolster the widespread implementation of evidence based CIH 
approaches for individuals with back pain from populations that experience health disparities (BP -
PEHD). The project utilizes mixed methods and will occur over two phases (R61/R33, see Figure 1).   
 
6.1 R61 A IMS & TRANSITION MILESTONES  
 
Phase I (R61) . We will conduct the necessary planning and preparations leading to a randomized 
feasibility study including co -development and assessment of Partners4Pain, a self -management 
program comprised of evidence based CIH approaches (e.g., pain education, mindful ness, cognitive 
behavioral/pain copi[INVESTIGATOR_4262], back specific exercise) and Keys to Wellbeing (e.g., general health 
education and exercise).  
 
R61 Aim 1 . We will use mixed methods data collection from multiple levels of stakeholders to assess 
barriers and facilitators to participating in BP self -management and community supported programs. 
This data collection will augment the existing literature and the results of previous and ongoing studies 
by [CONTACT_473].  
24 
PRP Study Protocol V5 October 2023  R61 Aim 2 . Based on information gathered in R61 Aim 1, we will perform participatory intervention 
mappi[INVESTIGATOR_272883] -develop a community supported CIH self -management intervention program (and 
control) for BP -PEHD.  
R61 Aim [ADDRESS_333569] a feasibility study (n=30 to 60) to assess essential scientific and feasibility 
milestones  including:  
a. Finalizing and securing agreements and regulatory approvals  (IRB, NCCIH, IMC ) for all required 
protocols and plans (e.g. , clinical protocol, Data Safety and Monitoring Plan, Study Accrual and 
Retention Plan, etc.)  
b. Recruiting and enrolling  individuals with BP -PEHD and measuring recruitment and enrollment rates  
c. Delivering experimental and control interventions  and measuring intervention adherence and fidelity 
rates  
d. Data collection  by [CONTACT_272948]  
e. Stakeholder views of barriers and facilitators  to the above, including affordability, practicality, 
effectiveness, acceptability, safety, and equity and other factors that could affect the future full scale 
trial’s success  
 
The following specific transition milestones  have been approved by [CONTACT_175315] (NCCIH) . 
• Demonstrate the ability to recruit and retain subjects in the clinical study as follows:  
o Randomize at least 30 participants  
o 75% or more of randomized participants are from NIH -defined racial/ethnic 
health disparity groups  
o 80% or more of randomized participants are retained for primary outcome 
measurement at the end of the R61 study (2 month follow up) regardless of 
adherence to the intervention  
• Demonstrate that the delivery of the intervention(s) and the control intervention(s) 
under study can be delivered consistently , as defined by:  
o 85% or more of randomized participants engage in 1 or more sessions  
o 75% or more of randomized participants engage in at least 6 of 9 sessions  
• Demonstrate the safety and tolerability of the intervention(s) used in the study by:  
o 5% or less of randomized participants experience a severe or serious adverse 
event related to the intervention(s)  
o 75% or more of randomized participants attend at least 6 of 9 sessions  
o 75% or more of randomized participants are satisfied with assigned program  
• Demonstrate the fidelity of the intervention(s) used in the study by:  
o Program facilitators deliver 90% of session activities 90% of the time  
• Demonstrate the ability to collect study data by:  
o 80% or more of randomized participants complete follow up at 2 months (end 
of the R61 study)  
• Prior to submission of the written R33 transition request, submit R33 clinical study 
protocols and Data and Safety Monitoring Plan to NCCIH for review and approval   
o Submit the R33 clinical DSMP and SARP by [CONTACT_43401] [ADDRESS_333570] be reached before requesting transition to the R33 phase.   
 
25 
PRP Study Protocol V5 October 2023  6.2 R33 A IMS  
 
Phase II (R33) . Upon approval by [CONTACT_272949] (see above), we will conduct a full -
scale multi -level randomized hybrid effectiveness implementation trial (n=376) of the community 
supported CIH self -management program, Partners4Pain , compared to the active control, Keys to 
Wellbeing, both of which will have been optimized and feasibility tested in Phase I.  
 
R33 AIM 1.  To assess the relative effectiveness of Partners4Pain versus Keys to Wellbeing in terms of:  
a. Primary effectiveness outcomes of pain intensity and interference over [ADDRESS_333571] and inform sustained translation of the program with community partner organizations  
 
7 RISK/BENEFIT ASSESSMENT  
 
7.1 OVERVIEW OF RISK/BENEFIT  
 
The risks differ across study phases and aims; these are summarized in Table 2 and Section 7.3 . 
 
Table 2. Risks According to Study Phase and Aims  
Study Phase (Aims)  Approach 
(Population)  Risks  Risk Level  
Phase I (R61 Aims 1, 2)  Quality Improvement 
Activities (Community 
Stakeholders)  Breach of Confidentiality  Minimal  
Phase I (R61 Aim 3)  Randomized Pi[INVESTIGATOR_56548]  
(Study Participants 
with Back Pain)  Breach of Confidentiality  
Completing Health Surveys  
Group Based Behavioral Interventions  
Natural History of Pain  Low 
Phase II (R33 Aims 1 -3)  Randomized Hybrid 
Effectiveness -
Implementation Trial  
(Study Participants 
with Back Pain ) Breach of Confidentiality  
Completing Health Surveys  
Group Based Behavioral Interventions  
Natural History of Pain  Low 
Phase II (R33 Aim 3)  Quality Improvement 
Activities  
(Community 
Stakeholders)  Breach of Confidentiality  Minimal  
 
7.2 BENEFITS  
 
26 
PRP Study Protocol V5 October 2023  7.2.1  QUALITY IMPROVEMENT ACTIVITIES (R61/R33)  
 
The benefits to  stakeholders taking part in the Quality Improvement Activities (R61, R33) include 
experiencing satisfaction in contributing views and opi[INVESTIGATOR_272890] -PEHD.  
 
7.2.2  RANDOMIZED  PI[INVESTIGATOR_272891]  (R61) & RANDOMIZED  TRIAL  (R33)  
 
The benefits to  participants  of the Randomized Pi[INVESTIGATOR_16116] (R61) and Randomized Trial (R33)  include:  
• Learning new information about pain and ways to take care of it  
• Learning new information about overall health and wellbeing  
• Experiencing health benefits, including decreased stress and increased wellbeing  
• Experiencing improvement in pain symptoms  
• Experiencing improvement in the ability to do daily activities  
 
7.3 RISKS  
 
7.3.1  QUALITY IMPROVEMENT  ACTIVITIES  (R61, R33)  
 
The risks to stakeholders taking part in the Quality Improvement Activities (R61, R33) are considered 
minimal.  
• Breach of Confidentiality.  
o New information will be gathered from stakeholders regarding their views and opi[INVESTIGATOR_272892]. This information is not anticipated to place 
individuals at risk of criminal or civil liability or be damaging to the subjec ts’ financial 
standing, employability, educational advancement, or reputation.  
o Secondary research data  will also be used , including non-identifiable data from previous IRB 
approved studies .  
 
7.3.2  RANDOMIZED  PI[INVESTIGATOR_272891]  (R61) & RANDOMIZED  TRIAL  (R33)  
 
The risks to participants of the Randomized Pi[INVESTIGATOR_16116] (R61) and Randomized Trial (R33) are considered 
low.  
• Breach of Confidentiality.  
o New information will be gathered from participants and is not anticipated to place 
individuals at risk of criminal or civil liability or be damaging to the subjects’ financial 
standing, employability, educational advancement, or reputation.  
• Completing Health Surveys. Participants will be asked to complete health surveys as part of the 
screening and follow up data collection; they may feel uncomfortable answering questions they 
feel are too personal.  
• Taking Part in Group Based Behavioral Interventions. Participants will be asked to take part in 
group behavioral interventions (via Zoom or in -person); the  interventions  are not physically 
[ADDRESS_333572].  Some 
participants may experience some anxiety or nervous ness when participating in  group activities . 
o Partners4Pain (Experimental Intervention).   Risks associated with the experimental 
behavioral intervention may occur in program sessions and practicing on one’s own. 
Expected risks are mild short -lasting physical discomfort (e.g., muscle and joint soreness) as 
a result of performing short periods of back -specific and general exercises (~5 -15 minutes); 
participants might also feel emotional when doing the brief mind -body practices (~5 
minutes) which include mindfulness and behavioral copi[INVESTIGATOR_4262] (e.g., relaxed 
breathing, guided imagery, progre ssive muscle relaxation).  
o Keys to Wellbeing (active control intervention).  Risks associated with the active control 
intervention may occur in program sessions and practicing on one’s own. Expected risks are 
mild short -lasting physical discomfort (e.g., muscle and joint soreness) as a result of 
performing short periods of general  exercises; participants might also feel emotional when 
doing the brief workbook exercises (~5 minutes) that ask them to reflect on different areas 
of their health and wellbeing.  
• Natural History of Pain . People with back and neck pain that is chronic in nature often 
experience fluctuations in pain severity, location, character, and quality; such fluctuations may 
be study related (e.g., due to engaging in exercises) or unrelated (e.g., aggravated by [CONTACT_272950]).  
 
7.4 RISK MITIGATION  
 
The following describes how risks will be minimized.  
 
• Breach of Confidentiality: All staff will complete UMN required training on HIPAA, data safety, 
and the Responsible Conduct of Research prior to working on the project. Data will be stored 
and accessed following UMN policies for data privacy and confidentiality (SEE SECTION 16.3).  
Identifiable data will be stored on password protected and HIPAA compliant databases and will 
only be accessed using HST ( Health Sciences Technology ) issued and maintained computers. All 
identifiable data will be removed from datasets used for analysis and all published reports will 
be summary in nature with no identifiable information for individual participants. Secondary 
research data from completed and ongoing studies will be limited to summarized findings from 
reports without identifiable information fo r individual participants.  
• Completing Health Surveys: We will provide an explanation for why we are asking questions 
that may be considered personal and allow participants the ability to not answer any question 
they don’t feel comfortable answering.  
• Taking Part in Group Based Behavioral Interventions: The behavioral interventions include 
activities and exercises that are  suitable for a range of abilities and preferences . Participants will 
also have the ability to  refrain from participating in activities that feel uncomfortable. Program 
facilitators will be trained and certified by [CONTACT_272951] a manner that optimizes patient safety. This will include 
how to monitor for potential emotional or physical  discomfort during session activities and how 
to implement safety protocols if needed. All participants will be encouraged to contact [CONTACT_272952] y side effects or adverse events that occur. 
Participants who experience a potential adverse event will be contact[CONTACT_426] a study team 
member to ensure safety protocols are followed and gather information for adverse event 
28 
PRP Study Protocol V5 October 2023  reporting. Adverse events impacting participant safety may result in withdrawal from the study 
intervention.  
• Natural History of Pain: We will provid e information to participants about the natural history of 
pain  and how to manage fluctuations.  They will also be encouraged to contact [CONTACT_272953].  Participants will 
have no restrictions on the care they can receive for their back or neck pain.  
 
[ADDRESS_333573] (see Figure 1).  
 
Phase I (R61)  includes mixed methods quality improvement activities and a randomized pi[INVESTIGATOR_799].  
Phase II (R33)  includes a mixed methods randomized hybrid effectiveness -implementation trial and 
mixed methods quality improvement activities.  
 
8.2 STUDY RATIONALE  
 
Rationale for Community Engaged Approach:  
There are several barriers to participating in research that have been identified in our own and others ’ 
work, especially among those from PEHD.82,[ADDRESS_333574] of community 
engaged research.80 
 
Rationale for Experimental Intervention: The Partners4Pain program was chosen as the experimental 
intervention  based on the literature supporting the effectiveness and safety of the individual CIH self -
management approaches ( see Table 1) of which it is comprised. There has been very little research to 
date that has investigated the combination of evidence -based CIH approaches, especially in community -
based settings and for individuals with BP -PEHD. As a consequence, it is important to assess the 
feasibility  of a combined CIH intervention ; the extent to which it meets participants’ needs can be 
implemented within community partner organizations in a fashion that facilitates long term adoption.  
 
Rationale for Control Intervention: The Keys to Wellbeing program controls for contextual factors 
including time, attention, delivery format, and intervention materials (workbooks, videos). The rationale 
for the choice of comparison intervention is based on feedback from community partners and our 
Community Advisory Team. They have expressed a desire for interventions that are useful to 
participants (versus a no -treatment control), especially  given the distrust in research among individuals 
[ADDRESS_333575] not assessed it however  in populations with BP -PHED. Thus, it is 
important to assess the feasibility of the control intervention in individuals with BP -PEHD.   
 
8.3 UNDERLYING MODELS & FRAMEWORKS  
 
Engaging communities in CIH research for  BP is inherently complex and requires established models a nd 
frameworks to guide the work .24,30,[ADDRESS_333576] based on insights from our community partners,  experience of the investigators, 
and the scientific literature (see  Introduction) . It is informed by [CONTACT_272954][INVESTIGATOR_272893]  (see Table 3).   
 
Table 3. Models and Frameworks Used in Project  
Framework or 
Model  Rationale for use  Application in Project  
RE-AIM 
Framework95 Provides overarching guidance for ensuring 
relevant contextual factors that can impact 
study implementation and translation, are 
considered throughout the project lifespan  
 Shapes ‘quality improvement 
activities’ and ‘disparity 
mitigating’ measures of reach, 
effectiveness, adoption, 
implementation and 
maintenance; informs ‘quality 
improvement analyses’  
ConNECT 
Framework80 Ensure s greater and sustained consideration to 
how the researchers work with communities 
who experience health disparities. Includes 
guiding attention to social contexts; fostering 
norms of inclusion; ensuring equitable diffusion 
of innovations; harnessing commun ication 
technology; and prioritizing community 
engagement t raining for study team members  Shapes conduct of entire 
project a nd informs ‘quality 
improvement analyses’  
Dynamic 
Biopsychosocial 
Model96 Facilitates consideration of the complex 
reciprocal interactions between the evolving 
biopsychological person with BP and their 
external, social environment. This is essential for 
providing insights into pain sufferers’ whole -
person needs, and BPS risk and  protective 
factors that may serve as barriers and 
facilitators to BP -PEHD engagement in self -
management72 Informs the 
design/development of the 
intervention and choice of 
outcome measures; informs 
‘quality improvement analyses’  
COM -B model72 A comprehensive behavioral model that 
provides guidance for assessing and addressing 
an individual ’s capability, opportunity , and 
motivational needs to achieve desired Informs the ‘quality 
improvement analyses’ that 
help identify individuals’ needs; 
informs the design/  
30 
PRP Study Protocol V5 October 2023  behavioral outcomes; considers affordability, 
practicality, effectiveness/cost -effectiveness, 
acceptability, safety, and equity  development of intervention by 
[CONTACT_272955]  
 
9 STUDY POPULATION  
 
9.1 STUDY POPULATION DEFINITIONS  
 
Community engaged research and implementation designs require multiple levels of participation  in a 
range of study activities (see Figure 1). Study population definitions are summarized below  in Table 4.  
 
Table 4. Study Population Definitions and Nature of Participation  
Population  Definition  Nature of Participation (e.g. Study 
Activity, Aim)  
Community 
Stakeholders  Individuals from local communities whose 
participation is limited to sharing views and 
opi[INVESTIGATOR_272894]/facilitators to interventions, 
study approaches  
 
INCLUDE:  
Community Members : Individuals from 
populations who experience health disparities 
(PEHD) who have experiences dealing with pain 
themselves or helpi[INVESTIGATOR_272895] (e.g., caregivers, clinicians, etc.)  
 
Community Facilitators:  Individuals who currently 
facilitate or could facilitate similar intervention 
programs as to what is being examined in the 
project  
 
Community Partner Organization Leadership : 
Individuals in leadership positions at Community 
Partner Organizations (YMCA of the North, YWCA 
St. Paul, Hue -MAN Partnership ) R61 Quality Improv ement Activities 
(Aims 1 -3) 
 
R33 Quality Improvement Activities 
(Aim 3)  
Study Participants  Individuals with back pain from populations who 
experience health disparities (BP -PEHD) and meet 
inclusion criteria for Randomized Pi[INVESTIGATOR_16116] (R61) 
or future Randomized Hybrid Effectiveness -
Implementation Trial  R61 Randomized Pi[INVESTIGATOR_16116]  
(Aim 3)  
 
R33 Randomized Hybrid 
Effectiveness Trial (Aims 1 -3) 
 
 
9.[ADDRESS_333577] self -reported chronic back pain (defined as pain in the low or mid back, or neck pain) which 
has lasted for [ADDRESS_333578] a score of 3 or higher on the self -reported Pain, Enjoyment of Life and General Activity (PEG) 
scale (0 to 10)  
6. Be a member of one or more of the following NIH -designated health disparity populations :* 
a. American Indian/Alaska Native  
b. Asian  
c. Black/African American  
d. Hispanic/Latino  
e. Native Hawaiian/Pacific Islanders  
f. Socioeconomically disadvantaged (annual household income less than $50,000 ) 
 
*This project focuses on back pain in populations that experience health disparities (BP -PEHD). These 
populations are underrepresented in research studies, have less access to resources for the 
management of back pain, and have poorer outcomes ( see Section 5, Introduction).  The study is offered 
in English, but supplementary materials are available in Spanish for individuals where English is a second 
language. Supplementary materials may also be offered in other languages.  
 
9.[ADDRESS_333579] six months because the mindfulness and behavioral 
mind -body practices (e.g., meditation, progressive muscle relaxation, etc.) in the experimental 
intervention may aggravate symptoms of severe mental illness  
2. Active psychotic symptoms, suicidal ideation, or manic epi[INVESTIGATOR_272896] #[ADDRESS_333580] on health outcomes  
4. Dementia – Mini Mental State Exam score of 23 or lower for those with suspi[INVESTIGATOR_272897] (e.g. , not being able to follow directions for safe physical exercise)  
5. Self-reported pregnancy due to the fact that back pain is often associated with pregnancy and 
differs from non -pregnancy related back pain and thus might have different impacts on health 
outcomes  
6. Children under the age of 18 * 
 
*Children under the age of [ADDRESS_333581] consistent with NIH Policy and 
Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects 
(http://grants.nih.gov/grants/guide/notice -files/not98 -024.h tml).  A separate age -appropriate study for 
children is preferable for several reasons. Most importantly, the self-management education programs 
are directed toward adults, with content, activities , and exercises that may not be suitable for children. 
Further, interventions are provided  in group settings with facilitated discussions geared towards 
[ADDRESS_333582] unknown validity or reliability in younger populations.  
 
9.4 RECRUITMENT & RETENTION  
 
Potential Community Stakeholders for the R61 and R33 Quality Improvement Activities will be identified 
through the routine communication channels of our Community Partnership Organizations (e.g., system -
wide emails, newsletters, organizational meetings, pr esentations, etc.).  
 
Study Participants ( See Section 9.1 Study Population Definitions ) for the R61 Randomized Pi[INVESTIGATOR_272898] R33 Randomized Hybrid Effectiveness -Implementation Trial  will be identified as described below.  
 
9.4.1  RECRUITMENT PROCESS  
 
A range of recruitment strategies will be used to recruit Study Participants; these will be initiated 
approximately 3-6 months prior to screening activities  and will continue until enrollment is complete.  
These include:  
● Dissemination of print and digital recruitment materials via routine communication channels 
(emails, newsletters, etc.) through our Community Partner Organizations  and other Community 
Members  
● Giving study and health related presentations in the community to raise awareness about the study  
● Participating in local community events (e.g., health fairs) where dissemination of recruitment 
materials is encouraged  
● Using paid advertising (e.g., digital , print , and radio ads) in local media outlets with reach to PEHD  
● Listing study on ResearchMatch, an electronic volunteer recruitment registry  
● Distributing print  and digital  flyers  and post -cards  on UMN campuses and in the community  
● Including information about the study in UMN affiliated newsletters (e.g., The Center for Spi[INVESTIGATOR_25824] 
& Healing, Office of Public Engagement, the Urban Research and Outreach -Engagement  Center  
(UROC) , etc.)  
● Posting information about the study on UMN affiliated social media (e.g. , The Center for Spi[INVESTIGATOR_25824] 
& Healing  and UROC  Facebook and Twitter accounts) and websites (e.g., the School of Nursing, the 
Center for Spi[INVESTIGATOR_25824] & Healing, as well as a unique study landing page)  
● Sharing information about the study with other study investigators who have mechanisms in place 
to query individuals during the consent process regarding their interest in being contact[CONTACT_272956]  
 
9.4.2  SOURCE & IDENTIFICATION OF POTENTIAL PARTICIPANTS  
 
Potential Study Participants will self -identify by [CONTACT_272957] . We will NOT access private/protected records (e.g., electronic medical 
records) to identify potential participants.  
[ADDRESS_333583]. Study participants will be compensated for the 
following study activities:  
• $20 for each baseline screening visit attended ($40 total)  
• $30 for each of the educational program sessions attended ($270 total)  
• $20 for each follow -up assessment completed ($20 total in R61; $60 total in R33)  
 
Total potential compensation for study participants will be $330 during the R61 and $370 during the 
R33.  
 
Community Stakeholders participating in formal interviews and focus groups will be compensated $ [ADDRESS_333584] decades of experience successfully 
addressing these challenges. We will implement the follo wing strategies used in previous studies to 
facilitate study participant engagement in the interventions and data collection:  
● Research staff will routinely track all study visits/time points per participant (screening and 
intervention session, follow -up) and will work closely with the Community Facilitators and 
Community Coordinators to devise timely solutions for mitigating rete ntion issues.  
● We will offer a range of program session times to accommodate participants’ needs; this 
includes early mornings , day, and evenings. Saturday appointments are also an option, as 
needed. Programs will be offered in different formats (in -person, videoconference) with our 
host Community Partner Organizations to accommodate participant preferences and needs.  
● If participants need to miss a program session, they will be able to view intervention session 
educational and skill videos by [CONTACT_272958].  
● All participants will be provided reminders of their study related visits.  
● Participants will be provided detailed instructions on how to find Community Partner 
Organization sites for in -person visits; transportation instructions including bus, train, and 
34 
PRP Study Protocol V5 October 2023  interstate routes will be included. Free, easily accessible parking will be made available to study 
participants.  
● Transportation services to and from study visits will be provided to participants, as needed, 
using Transportation Plus , a Twin Cities based company . The study team will arrange taxi 
services for the participant. Prior to initiating the ride, participants will provide verbal consent to 
have their contact [CONTACT_3031] (e.g., name, address, phone number) shared with Transportation 
Plus. Verbal consent will be captured in the study record. Transportation is paid for by [CONTACT_1758]; 
participants will not incur out of p ocket costs.  
● Participants will receive regular reminders (automated via text, email, or other methods 
depending on participant preference) to complete self -report questionnaires (SRQs). Study staff 
will closely monitor completion and contact [CONTACT_272959].  
● During screening, study staff will provide a detailed description of the study, including what 
participants can expect with respect to the commitment necessary to preserve the integrity of 
the project prior to enrollment. Participants will be given as much  time as needed to decide if 
they want to participate.  
● The research team will use patient -centered communication to foster trusting relationships 
between the study staff and participants. If challenges arise with participants, the study team 
(e.g., study coordinators) will talk openly with participants about t hese challenges, without 
pressure. Further, study staff will make efforts to keep in touch with study participants using 
participants' preferred contact (e.g., email, phone call), especially after completion of the 9 -
week intervention phase , to facilitate follow up.  
 
 
9.4.6  STRATEGIES FOR ADRESSING BARRIERS TO RECRUITMENT & RETENTION OF 
POPULATIONS WHO EXPERIENCE HEALTH DISPARITIES (PEHD)  
 
• To improve researchers’ cultural competency, the research team are provided dedicated 
professional time to engage in ongoing professional development with Community Partner 
Organizations, including the YMCA of the North’s Equity Innovation Center . 
• To address the mistrust individuals from PEHD may have in the research process, we will:  
o Work with Community Partner Organizations and Community Champi[INVESTIGATOR_272899]  
o Continue to encourage and support ongoing research staff participation in community 
volunteer activities and events  
o Hire Community Coordinators in consultation with our Community Partner 
Organizations to facilitate interfacing with community members  
o Work with an established Community Advisory Team which is guided by a Team Charter, 
with clearly defined roles and processes for collaborative decision making  
o Provide equitable compensation for Community Advisory Team Members, Community 
Consultants, Community Coordinators, Community Stakeholders , and Study Participants  
• To address logistical issues, including access to technology, we will work with Community 
Partner Organizations to conduct study activities at sites located in and/or easily accessible to 
communities of color and lower socioeconomic status . In addition, we will provide access to 
transportation services for study participants to attend study visits.  
35 
PRP Study Protocol V5 October 2023  • To address the need to be responsive to community needs , we will involve Community 
Stakeholders, the Community Advisory Team , and our Community Partner Organizations across 
the research process . 
 
10 ENROLLMENT PROCEDURES  
 
10.1 NUMBER OF STUDY PARTICIPANTS  
 
A total of 30 -60 individuals will be enrolled for the  R61 Randomized Pi[INVESTIGATOR_16116] ; 376 will be enrolled for 
the R33 Randomized Hybrid Effectiveness -Implementation Trial . 
10.2 SCREENING & ENROLLMENT  
 
Screening and enrollment for the R61 Randomized Pi[INVESTIGATOR_272900] R33 Randomized Hybrid 
Effectiveness -Implementation Trial will take place over three events. Potential participants will be 
initially screened  for basic eligibility criteria using a web -based survey that can be completed online or 
over the phone with study staff. Interested and eligible individuals will be invited to a baseline 1  
screening visit which will occur face -to-face either in person or using videoconferencing technology. 
Participant s who are eligible will attend a baseline 2  screening visit conducted either face -to-face or over 
the phone. Eligible participants will be enrolled in the study at the conclusion of baseline 2 (also see 
Schedule of Assessments and Sections 13.1 to 13.4 for specific details regarding activities at each visit).  
10.3 RANDOMIZATION & BLINDING  
 
Eligible individuals will be enrolled and randomized using blocked randomization (with varying block 
sizes) following stratification for session offerings (e.g., Summer 202 3 - Saturday mornings). Computer 
generated random treatment assignments will be prepared by [CONTACT_272960] (the electronic study database) at the time of enrollment to 
preserve allocation concea lment. All study staff responsible for screening and enrollment procedures 
will be blinded to upcoming treatment assignments. The Co -PIs, select Co -Investigators, and the study 
statistician will be blinded until the study database is locked for analysis. The Co -PIs are authorized to be 
unblinded when needed for safety -related processes ( e.g., decisions to withdraw participants from the 
intervention following adverse events).  
11 INTERVENTIONS  
 
11.1 INTERVENTION OVERVIEW  
 
Both the experimental (Partners4Pain) and active control (Keys to Wellbeing) interventions  will be  
informed by [CONTACT_272961] R61 Aims 1 and 2 and research done previously by [CONTACT_473] 
(R33AT009110, NH170001, UH3AT008769, R34AT011209).1-10 The Template for Intervention Description 
and Replication (TIDieR) checklist has been and will continue to be used to guide the description of the 
study interventions97 to facilitate future results interpretation, as well as dissemination and replication. 
Consistent with the RE -AIM and ConNECT frameworks guiding this project, we anticipate the 
interventions will be further shaped and adapted based on stakeholder feedback  to meet the needs of 
[ADDRESS_333585] (83 -92% across in -person and videoconference delivery 
formats) and no serious adverse events attribut able to the interventions have been recorded (n=>500 
participants across studies, R33AT009110, NH170001).  
 
Table 5. TIDieR Intervention Elements Common to Both Groups  
Intervention Specific 
Participant Resources  Materials and resources that support specific intervention content (see 
descriptions for Partners4Pain and Keys to Wellbeing). Includes print and 
electronic workbooks; access to education and skill training videos via a 
website for viewing in multiple formats (e.g., cell phone, computer 
tablet, etc.)  
Facilitator Materials  Print and electronic manual with session checklists and safety protocols; 
Google Slide session presentations with embedded expert -led 
educational and skill training videos; technology and related peripherals 
(e.g., headsets) as needed  
Facilitator Training  Community Facilitators from our Community Partner Organizations with 
experience leading group programs; 30 hours of competency -based 
training by [CONTACT_272962] -led group sessions; includes viewing of expert -narrated videos 
specific to each intervention’s content , workbook reflection activities , 
and facilitator -led group discussions  
 
Participants are encouraged to practice in between sessions using the 
provided intervention -specific resources (e.g. , workbooks, videos, etc.).  
Delivery Format  Sessions offered in -person, via videoconference, or hybrid depending on 
community partner organization and participant needs. Group sessions 
with 7-16 participants per group  
Location  See participating locations listed in section 4.3 
Timing, Schedule  One session per week for 9 weeks  
90 minutes per session  
Similar to other educational programs offered in community partner 
organizations.  
Tailoring  Participants will be encouraged to practice at home, focusing on 
intervention specific content that meet s their needs  
Fidelity  10% of the interventions will be monitored by [CONTACT_2792] , either 
in-person or remotely using a fidelity checklist which will assess  
completion of required session activities; review of weekly session 
facilitator documentation in REDCap regarding ability to deliver session 
activities as planned, including rationale for activities not completed  
 
11.2 EXPERIMENTAL INTERVENTION (PARTNERS4PAIN)  
 
37 
PRP Study Protocol V5 October 2023  Partners4Pain is informed by [CONTACT_19569] -B model for behavioral interventions; it postulates that to 
achieve desired behavioral outcomes (e.g. , engagement in positive self -management behaviors such as 
increased activity, decreased medication use, etc.), interventions must address an individual’s capability , 
opportunity , and motivational related needs .72 Application of the COM -B model provides guidance for 
assessing and addressing needs more specifically (e.g. , what knowledge, skills, and resources are 
needed?) and mappi[INVESTIGATOR_272901]. Importantly, the COM -B model considers affordability, practicality, 
effectiveness/cost -effectiveness, acceptability, safety, and equity  - all critical considerations for 
implementation and translation of an intervention over the longer term, particularly for populations 
experiencing health disparities.[ADDRESS_333586] pain and behavioral outcomes by [CONTACT_272963] -PEHD needs for effective 
pain self-management behaviors. Content unique to Partners4 Pain includes education, skills training , 
and support in evidence based CIH strategies, (e.g. , pain education; BP specific mobility, strength , and 
stabilization exercises; mindful movement and meditation; progressive muscle relaxation, guided 
imagery, etc.) augmented by [CONTACT_272964] (e.g. , action 
planning, problem solving, graded tasks, social support, etc.) which w ill be built into the program.72,100 
An important feature of the program will be to provide individuals with resources and support that will 
empower them to identify what they need (e.g. , more information, specific exercises, more or less 
support from others, etc.) and how to choose which resources are appropriate for them. This approach 
to self -management is currently being used by [CONTACT_272965] (R33AT009110, 
NH1700 01, UH3AT008769, R34AT011209).  
 
11.3 CONTROL INTERVENTION (KEYS TO WELLBEING)  
 
Keys to Wellbeing is a credible, active comparison for the experimental intervention and  will control for 
contextual fac tors between groups (S ee Table 5). It will do so by [CONTACT_272966] -PEHD related capability needs, specifically general knowledge and 
awareness of health and wellbeing. Topi[INVESTIGATOR_272902], finding meaning and purpose, sorting health facts from fiction, addressing mental he alth, 
and keepi[INVESTIGATOR_272886]. This intervention was developed to serve as an active comparison for another 
CIH self -management study focused on mindfulness (R33AT009110). Adherence and satisfaction rates 
have been 89% and 79% respectively, indicating i ts robustness as a credible control.  
 
11.[ADDRESS_333587] 10% of the sessio ns will be assessed either in person or via 
videoconference. We will use adapted fidelity instruments used in previous studies. Fidelity of 
intervention delivery will also be assessed by [CONTACT_272967].  
 
11.[ADDRESS_333588] 70% of 
session activities is consider ed sufficient for attendance. Engagement and satisfaction with study 
interventions will be queried during the month two assessment.  
 
11.6 CONCOMITANT THERAPY  
 
Participants may continue to use self -management strategies (e.g., over -the-counter medications ,  
exercise) or provider -based interventions such as prescription medications or complementary and 
integrative therapi[INVESTIGATOR_014] (e.g. , acupuncture, manual therapy) for the duration of the study. Use of 
medications, self -management strategies, and provider -based therapi[INVESTIGATOR_272903].  
 
11.[ADDRESS_333589] is assessing community -based self -management programs for spi[INVESTIGATOR_272904]. Medical providers are not routinely available within community -
based self -management programs, thus rescue medication ther apy will not be provided by [CONTACT_1758]. 
Participants requiring evaluation and provider -based management for back pain will be referred to their 
health care provider.  
 
12 INTERVENTION DISCONTINUATION & PARTICIPANT WITHDRAWAL  
 
The following describes intervention discontinuation and study participant discontinuation/withdrawal 
for the  R61 Randomized Pi[INVESTIGATOR_272900] R33 Randomized Hybrid Effectiveness -Implementation Trial .  
 
12.1 DISCONTINUATION OF STUDY INTERVENTION  
 
A study participant may discontinue from the experimental or active control interventions, but not from 
the study overall. In such cases, remaining study procedures will be completed as indicated by [CONTACT_17143]. If a significant finding (e.g., development of an exclusion criterion) is identified after 
enrollment, the investigator or qualified designee wil l determine if any change in participant 
management is needed. Any new significant findings will be reported as an adverse event (AE).  
 
All efforts will be taken to facilitate study participants’ completion of the study interventions. However, 
participants may be discontinued from their assigned intervention if , for example:  
• They develop an exclusion criterion (new or not previously recognized) that would make it 
unsafe for them to continue  
• They exhibit s ignificant study intervention non -compliance (e.g., disruptive  or unsafe behavior)  
• Any adverse event (AE), medical condition, or other situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
39 
PRP Study Protocol V5 October 2023  • New evidence emerges which  suggests it is unsafe for the participant(s) to proceed with the 
study  
• Participant withdraws consent to continue  
 
The data to be collected at the time of study intervention discontinuation, and for the remainder of the 
study will include the following:  
• Reason for intervention discontinuation and methods for determining the need to discontinue  
• Number of completed intervention visits  
• AE/SAE information, if indicated  
• Self-report surveys will continue to be administered as scheduled, even though the participant 
has discontinued study interventions  
 
12.[ADDRESS_333590]. An 
investigator may also discontinue a participant from the s tudy for reasons including, but not limited to, 
the following:  
• Participant develops an exclusion criterion (new or not previously recognized) that would make 
it unsafe for them to continue  
• Participant exhibits s ignificant study intervention non -compliance (e.g., disruptive  or unsafe 
behavior)  
• Any adverse event (AE), medical condition, or other situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
• New evidence emerges which  suggests it is unsafe for the participant(s) to proceed with the 
study  
• A major change occurs in the participant's life (e.g., incarceration, death)  
• Study closure by [CONTACT_272968]  
• Participant withdraws consent to continue  
 
The reason for participant discontinuation or withdrawal from the study will be recorded on the Study 
Completion Case Report Form (CRF) in REDCap  and participants will be notified . Subjects who sign the 
informed consent form and are randomized but do not receive the study intervention will not be 
replaced. Subjects who sign the informed consent form, are randomized and receive the study 
intervention, and subsequently withdraw, or are discontinued from the  study, will not be replaced . 
 
12.[ADDRESS_333591] 3 phone calls (which will be documente d in the study record). Further details on processes 
for enhancing study retention are provided in section 9.4. 
40 
PRP Study Protocol V5 October 2023  13 STUDY ASSESSMENTS & PROCEDURES  
 
The following describes study assessments and procedures for the R61 Randomized Pi[INVESTIGATOR_272900] 
R33 Randomized Hybrid Effectiveness -Implementation Trial .  
 
13.1 SCHEDULE OF ASSESSMENTS  
 
Table 6  details the schedule of assessments for Study Participants in the R61 Randomized Pi[INVESTIGATOR_272905] R33 Randomized Hybrid Effectiveness -Implementation Trial .  
 
Table 6. Schedule of Assessments for Study Participants** (R61 Randomized Pi[INVESTIGATOR_272877] R33 
Randomized Trial)  
 Initial 
Screen  BL1 BL2 Intervention 
Sessions 1 -9 Month 2  
(-21 to 
+28 days)  R33 Only  
Month 4  
(-21 to +28 
days)  Month 6  
(-21 to +28 
days)  
Flow Data for Feasibility Outcomes+  
Feasibility of recruitment, enrollment, 
intervention, and data collection rates  X X X X X   
Baseline Assessments   
PhenX toolkit: Demographics & Core 
SDH Measures X X X     
Informed Consent  X X X     
Inclusion/Exclusion Criteria  X X X     
Randomization    X     
Intervention Assessments  
Intervention Attendance, Session 
Activities, Intervention Administration 
Form     X    
Effectiveness Measures * 
Pain intensity   X X  X X X 
Pain interference   X X  X X X 
Pain impact  and frequency   X X  X  X 
Self-efficacy for managing chronic 
conditions    X  X X X 
Domain specific life satisfaction    X  X X X 
Physical functioning    X  X X X 
Pain catastrophizing    X  X  X 
Interoceptive awareness    X  X X X 
Satisfaction/Improvement      X X X 
Medication use (including opi[INVESTIGATOR_2438])    X  X X X 
Participation in social roles    X  X  X 
CIH self -management use    X  X X X 
Healthcare use    X  X X X 
Sleep disturbance/duration    X  X  X 
Depression    X  X  X 
Anxiety    X  X  X 
Substance use    X  X  X 
Implementation and Disparity Mitigating Measures (guided by [INVESTIGATOR_21392] -AIM, COM, ConNECT)  
Views and opi[INVESTIGATOR_272906], 
facilitators to interventions and study 
participation  (see Table 9, Study 
Participants for details)  X X X  X   
Satisfaction with and use of specific 
program activities      X X X 
COM Assessment Survey      X   
41 
PRP Study Protocol V5 October 2023   Initial 
Screen  BL1 BL2 Intervention 
Sessions 1 -9 Month 2  
(-21 to 
+28 days)  R33 Only  
Month 4  
(-21 to +28 
days)  Month 6  
(-21 to +28 
days)  
Supportive Environmental and 
Relational Alliance Survey      X   
Other Measures  
Adverse events /side effects     X X X X 
Study Completion Form      X (R61)   X (R33)  
**Schedule of quality improvement data collection activities can be found in Table 9  
*Effectiveness measures collected in R61 for purpose of assessing data collection feasibility only  
+Flow data is collected for the purposes of assessing feasibility areas for refinement in the R61 pi[INVESTIGATOR_799] (including asse ssing RE -AIM factors)  
 
 
13.[ADDRESS_333592] electronic data entry in REDCap 
administered to the participant either through a web -based survey or a phone screen with trained study 
staff. Both processes will include an intr oduction to the study and participants will be required to 
provide verbal or electronic consent prior to providing information ( See section  16.1 ). Participants will 
be asked a limited number of questions regarding basic eligibility criteria and demographics to ensure 
they qualify (e.g., age, race/ethnicity, history of chronic back or neck pain, pregnancy). Study staff will 
speak with eligible individuals to answer any questions they may have and schedule them for a first 
baseline screening visit.   
13.2.[ADDRESS_333593] up to 90 days after the initial screen described above. This 
evaluation will be conducted face -to-face either in person or via videoconference and will included the 
following activities:   
● Trained study staff will perform informed consent (see Consent Procedures in Section  16.1 ) 
● The Folstein  Mini -Mental Status Examination (MMSE) will be administered to participants if 
cognitive impairment is suspected (e.g., repeating questions, unable to respond to/follow basic 
instructions)  
● Participants will complete a self -report web -based survey of questions to assess eligibility and 
collect baseline assessments for the following:  
o Demographic, occupational, and pain and health -related characteristics, including 
recommended common data elements for the study of pain117,130  
o Self-reported effectiveness and implementation outcome measures detailed in Table 6 ( see 
section 14.2  for detail on individual measures)  
● Staff will schedule Baseline Two screening visit  
13.2.[ADDRESS_333594] up to 90 days after BL1. This evaluation may be conducted 
in-person, via videoconference, or by [CONTACT_272969]:  
● Trained study staff will confirm consent for participation (See Section 16.1 ) 
42 
PRP Study Protocol V5 October 2023  ● Participants will complete a brief self -report web -based survey to confirm eligibility for exclusion 
criteria that may have developed after the BL1 evaluation (e.g., pregnancy, cancer treatment)  
● Participants will complete baseline assessment for self -reported outcome measures listed in 
Table 6 ( see Section 14.2  for detail on individual measures)  and the PhenX toolkit measure for 
discrimination in healthcare.101 
● Eligible participants will be enrolled in the study and randomized to either the Partners4Pain or 
Keys to Wellbeing intervention program.  
 
13.3 INTERVENTION SESSIONS  
 
The group interventions will start within 28 days of randomization. Community Facilitators will 
document attendance and presence for activities covered during weekly intervention visits using an 
intervention administration form in REDCap.  
 
13.4 FOLLOW -UP ASSESSMENTS  
 
Follow up assessments of Effectiveness and Implementation/Disparity Mitigating Measures  (see Table 6 
Schedule of Assessments ) will be completed 2 months  after the group interventions begin  for the R61 
Randomized Pi[INVESTIGATOR_272877] 2, 4 and 6 months  after the group interventions begin  for the R33 
Randomized Hybrid Effectiveness -Implementation Trial. Details on individual measures are provided in 
section 14.2.  
 
13.5 ADVERSE EVENTS & SERIOUS ADVERSE EVENTS  
 
13.5.1  DEFINITION OF ADVERSE EVENTS  
 
An adverse event (AE) is any untoward medical occurrence in a subject during participation in the R61 
Randomized Pi[INVESTIGATOR_16116], the R33 Hybrid Effectiveness -Implementation Trial, or with use of the 
interventions being studied. An adverse finding can include a sign, symptom, abnormal assessment 
(laboratory test value, vital signs, etc.), or any combination of these regardless of relationship to 
participation in the study. If there is any doubt as to whether an observation is an AE, the event will be 
recorded.   
13.5.2  DEFINITION OF SERIOUS ADVERSE EVENTS  
 
A serious adverse event (SAE) is one that meets one or more of the following criteria:  
• Results in death  
• Is life -threatening (places the subject at immediate risk of death from the event as it occurred)  
• Results in inpatient hospi[INVESTIGATOR_1081]  
• Results in a persistent or significant disability or incapacity  
• Results in a congenital anomaly or birth defect  
An important medical event that may not result in death, be life threatening, or require hospi[INVESTIGATOR_91403], based upon appropriate medical judgment, the event may jeopardize 
[ADDRESS_333595] and may require medical or surgical intervention to prevent one of the outcomes listed in 
this definition.  
13.5.3  CLASSIFICATION OF AN ADVERSE EVENT  
 
The following guidelines will be used to grade the severity of adverse events:  
• Mild: no intervention required; no impact on activities of daily living (ADL)  
• Moderate: minimal, local, or non -invasive intervention indicated; moderate impact on ADL  
• Severe: significant symptoms requiring invasive intervention; subject seeks medical attention, 
needs major assistance with ADL  
• Serious: results in death; life threatening; requires inpatient hospi[INVESTIGATOR_059]; results in persistent 
or significant disability; congenital anomaly or birth defect.  
13.5.4  RELATIONSHIP TO STUDY PROCEDURES   
 
All adverse events (AEs) will have their relationship to study procedures, including the intervention, 
assessed by a PI, or designee, on temporal relationship. The degree of certainty about causality will be 
graded using the categories below  (see Table 7 ). 
 
Table 7. Relationship of Adverse Events to Study Procedures  
Relatedness  Definition  
Definitely Related  There is clear evidence to suggest a causal relationship, and other possible contributing factors can 
be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible 
time relationship to study procedures administration and cannot be explained by [CONTACT_64758]. The response to withdrawal of the study procedures should be clinically 
plausible. The event must be pharmacologically or phenomenolo gically definitive.  
Probably Related  There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The 
clinical event, including an abnormal laboratory test result, occurs within a reasonable time after 
administration of the study procedures, is unlikely to be attributed to concurrent disease or other 
drugs or chemicals, and follows a clinically reasonable response on withdrawal.  
Potentially Related  There is some evidence to suggest a causal relationship (e.g., the event occurred within a 
reasonable time after administration of study procedures). However, other factors may have 
contributed to the event (e.g., the participant’s clinical condition, othe r concomitant events). 
Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as 
requiring more information and later be upgraded to “probably related” or “definitely related”, as 
appropriate.  
Unlikely to be 
related  A clinical event, including an abnormal laboratory test result, whose temporal relationship to study 
procedures administration makes a causal relationship improbable (e.g., the event did not occur 
within a reasonable time after administration of the study procedures) and in which other drugs or 
chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical 
condition, other concomitant treatments).  
Not Related  The AE is completely independent of study procedures administration, and/or evidence exists that 
the event is related to another etiology. There must be an alternative, definitive etiology 
documented.  
 
13.5.5  EXPECTEDNESS  
 
The PIs are responsible for determining whether an AE or SAE is expected or unexpected. An adverse 
event will be considered unexpected if the nature, severity, or frequency of the event is not consistent 
44 
PRP Study Protocol V5 October 2023  with the risk information previously described for the intervention and/or study (e.g., risk information in 
the consent form, natural history of the condition) . 
 
13.5.6  TIME PERIOD & FREQUENCY FOR EVENT ASSESSMENT & FOLLOW -UP 
 
The PI, or designee, will record all reportable events with start dates occurring any time after 
randomization until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. 
Study related AE/SAEs will be followed to stabiliz ation/resolution.  
 
13.5.7  ADVERSE EVENT & SERIOUS ADVERSE EVENT REPORTING  
 
Reporting for adverse events, serious adverse events, and other expedited events is summarized in 
Table 8.  
 
Table 8. Reporting for Adverse events, Serious adverse events, and Other events  
Event  Report to….  
 Reporting Time  
Serious AE or AE  – unexpected  and at least 
probably related  to the research procedures.  UMN IRB  The IRB defines prompt reporting to be within 5 
business days . If an RNI is not filed within 5 
business days, explain why the delay in reporting 
occurred and how prompt reporting will be 
ensured in the future.  
Serious AE – unexpected and related to the 
intervention  NCCIH PO; IMC  7 days  
Serious AE – anticipated or unrelated   
 NCCIH   
IMC 
IRB AE(s) will be summarized in IMC reports. IMC 
reports will be distributed to the IMC and NCCIH 
per the guidelines in the IMC Charter and DSMP. 
IMC reports will be submitted to the IRB as an RNI 
within 5 business days of the IMC meeting 
minutes being signed or sent to IMC in lieu of a 
meeting.   
Unexpected Death  or life -threatening AE related 
to the intervention  
 NCCIH Program 
Officer, IMC  3 days of the investigator becoming aware of the 
event  
Unexpected Death : Unexpected death of a locally 
enrolled participant whether considered related 
to the research or not.  Death is considered 
unexpected if the risk of death is not listed in the 
consent form  UMN IRB  The IRB defines prompt reporting to be within 5 
business days . If an RNI is not filed within 5 
business days, explain why the delay in reporting 
occurred, and how prompt reporting will be 
ensured in the future.  
Risk:  Information that indicates a new or 
increased risk, or a safety issue. For example:  
•  
• New information (e.g., an interim analysis, safety 
monitoring report, publication in the literature, 
sponsor report, or investigator finding) indicates UMN IRB  The IRB defines prompt reporting to be within 5 
business days . If an RNI is not filed within 5 
business days, explain why the delay in reporting 
occurred, and how prompt reporting will be 
ensured in the future.  
45 
PRP Study Protocol V5 October 2023  an increase in the frequency or magnitude of a 
previously known risk , or uncovers a new risk  
•  
• An adverse event that indicates a potential 
increase in risk or reduction in benefit (such as 
those that may prompt a change to the protocol 
or consent form)  
•  
• Protocol violation that harmed participants or 
others or that indicates participants or others 
might be at increased risk of harm  
•  
• Complaint of a participant that indicates 
participants or others might be at increased risk of 
harm or at risk of a new harm  
 
Confidentiality – unauthorized disclosure of 
confidential information   UMN IRB  The IRB defines prompt reporting to be within 5 
business days . If an RNI is not filed within 5 
business days, explain why the delay in reporting 
occurred, and how prompt reporting will be 
ensured in the future.  
PO: program officer; AE: adverse event; IRB: Institutional Review Board; UMN: University of Minnesota ; RNI: Report of New 
Information; IMC: independent monitoring committee; NCCIH: National Center for Complementary and Integrative Health  
 
13.5.[ADDRESS_333596]  
 
Reporting of certain events is required by [CONTACT_2371] (e.g., suspected child abuse, vulnerable adult abuse or 
neglect, excessive use of alcohol or use of controlled substances for non -medical reasons during 
pregnancy) and may be discovered during the study. If in formation becomes available that may require 
mandated reporting, study staff will contact [CONTACT_272970] (also see 
https://mn.gov/dhs/general -public/licensing/maltreatment -investigations/mandated -reporter -
resources ) 
 
13.5.9  REPORTING OF PREGNANCY  
 
Pregnancy, current or planned, at the point of enrollment is an exclusion criterion for the trial. Enrolled 
subjects who become pregnant may receive study interventions if there are no increased risks to the 
pregnant person or fetus. Approval will be sough t from the IRB prior to intervention continuation. Such 
participants  will be followed for the remainder of the study for outcome ascertainment. If treatment 
discontinuation is necessary, the reason for discontinuation will be reported in semi -annual reports to 
the Independent Monitoring Committee.  
 
13.6 UNANTICIPATED PROBLEMS  
 
This protocol uses the definition of Unanticipated Problems as defined by [CONTACT_272971] n 
Research Protections (OHRP). OHRP considers unanticipated problems involving risks to participants or 
others to include, in general, any incident, experience, or outcome that meets all the following criteria:  
46 
PRP Study Protocol V5 October 2023  • Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the subje ct population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_9156]); and  
• Suggests that the research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
 
13.6.1  UNANTICIPATED PROBLEMS REPORTING  
 
The PI, or designee, will report Unanticipated Problems (UP) Involving Risks to Subjects or Others 
(UPI[INVESTIGATOR_16104]) to the IRB within 5 business days of learning of the event. The UP report will include the 
following information.  
• Protocol identifying information: protocol title and number, PI [CONTACT_104847], and the IRB project 
number  
• A detailed description of the nature and severity of the event and the likely impact of the event 
on risk to study participants or others  
• Date the event occurred; date the study team became aware of the information  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP  
• A description of whether the information indicates a new or increased risk, or a safety issue  
• A description of any changes to the informed consent documents and plans for notifying 
participants, if necessary  
 
14 OUTCOMES  
 
The choice of outcomes has been guided by:  
• The RE-AIM Framework , to ensure future success of the trial and future long -term tran slation of 
the interventions  
• The ConNECT Framework , to ensure Community Stakeholders are engaged earlier and more 
frequently  in the research process  
• The h ybrid effectiveness -implementation trial design, to ensure simultaneous measures of 
effectiveness and implementation  are captured  
• The b iopsychosocial model , to ensure biophysical, psychological, and social measures relevant 
to back pain in populations who experience health disparities are addressed  
• Alignment with HEAL core and supplementary outcome measures  
 
14.1 R61 OUTCOMES  
 
The purpose of the R61 is to assess needs, optimize study intervention and approaches, and evaluate 
feasibility of the interventions and stud y approach es in preparation for the R33 Randomized Hybrid 
47 
PRP Study Protocol V5 October 2023  Effectiveness Trial. This will be accomplished by [CONTACT_272972][INVESTIGATOR_6153], as well as flow data (see 
below).  
14.1.1  VIEWS AND OPI[INVESTIGATOR_272907] -researcher views into the research process, and contribute to co -learning and co -
development, which are important features of community engaged research. Data collection methods 
will include survey questions  (closed - and open -ended) , interviews, focus groups, field notes; secondary 
analyses of previous IRB approved qualitative data  will also be used.  
 
The schedule of data collection of Community Stakeholder and Study Participant views and opi[INVESTIGATOR_272908] 9. This  information will augment the investigators previous and ongoing research and 
the scientific literature .10,82,89,90,[ADDRESS_333597] Population Level  Assess Needs; 
Optimize 
Interventions, 
Approaches  
(Pre-Pi[INVESTIGATOR_16116], 
Mixed Methods 
Quality Improve -
ment Activities)  Evaluate Feasibility, 
Areas for Refinement  
(Randomized Pi[INVESTIGATOR_56548])  
 Evaluate Effectiveness and 
Impact of Health Disparities ; 
Assess and Describe 
Implementation, Disparity 
Mitigating Factors  
(Randomized Hybrid 
Effectiveness -Implementation 
Trial)  Throughout 
Project, Time 
Independent (As 
they arise)  
Community Stakeholders  
Views, opi[INVESTIGATOR_272909]: barriers and facilitators 
to pain management, self -management 
identification of capability, opportunity 
and motivational (COM, BPS), 
implementation (RE -AIM), and disparity 
mitigating needs (RE -AIM, ConNECT, COM -
APEASE)  X  
  X 
Views, opi[INVESTIGATOR_272909]: solutions to address 
needs identified above  X  
  X 
Reactions, opi[INVESTIGATOR_272909]: resources and 
approaches for R61 Pi[INVESTIGATOR_16116] (e.g., 
recruitment materials, workbooks, videos, 
etc.)  X   X 
Views and opi[INVESTIGATOR_272910] R61 Pi[INVESTIGATOR_272911]; ideas for optimizing interventions 
and study approaches for R33 Randomized 
Trial   X  X 
Views and opi[INVESTIGATOR_272910] R33 Randomized 
Trial Results; ideas for addressing 
implementation and disparity mitigating 
needs to prepare for translation to 
community settings    X X 
Views/opi[INVESTIGATOR_272909]: intervention 
affordability, practicality, effectiveness, 
acceptability, safety, and equity; factors 
that will facilitate adoption, 
implementation, maintenance (RE -AIM, 
ConNECT) at community and 
organizational level    X X 
Study Participants  
Views/opi[INVESTIGATOR_272909]: barriers/facilitators to 
recruitment, enrollment; reach (RE -AIM)   X X  
[ADDRESS_333598] Population Level  Assess Needs; 
Optimize 
Interventions, 
Approaches  
(Pre-Pi[INVESTIGATOR_16116], 
Mixed Methods 
Quality Improve -
ment Activities)  Evaluate Feasibility, 
Areas for Refinement  
(Randomized Pi[INVESTIGATOR_56548])  
 Evaluate Effectiveness and 
Impact of Health Disparities ; 
Assess and Describe 
Implementation, Disparity 
Mitigating Factors  
(Randomized Hybrid 
Effectiveness -Implementation 
Trial)  Throughout 
Project, Time 
Independent (As 
they arise)  
Views/opi[INVESTIGATOR_272909]: extent to which 
program met capability, opportunity, 
motivational (COM) needs; facilitates 
implementation (RE -AIM)   X X  
Views/opi[INVESTIGATOR_272909]: intervention 
affordability, practicality, effectiveness, 
acceptability, safety, and equity; factors 
that will facilitate adoption, 
implementation, maintenance (RE -AIM, 
ConNECT) at individual level   X X  
Views/opi[INVESTIGATOR_272909]: ability of the study 
team to create supportive environment, 
develop relational alliances that motivate 
engagement (COM), are inclusive and 
culturally sensitive (ConNECT); factors that 
will facilitate adoption, implementation , 
maintenance at individual level   X X 
 
COM=Capability, opportunity, motivation from the COM -B model; RE -AIM=Reach, Effectiveness, Adoption, Implementation, Maintenance as 
defined by [CONTACT_39505] -AIM Framework  
 
14.1.2  FEASIBILITY OUTCOMES  
 
We will evaluate feasibility outcomes as part of the R61 Randomized Pi[INVESTIGATOR_272912], including rates of recruitment, enrollment, intervention acceptability/credibility, 
intervention fidelity. In addition, as part of det ermining feasibility, the funder (NCCIH) has approved 
specific transition milestones that must be met prior to moving forward with the R33 Randomized Trial 
(see Section 6.1).  
Feasibility measures include performance indicators for key study domains that will provide insight into 
the feasibility of conducting the future R33 Randomized Trial. They will also help us identify areas for 
refinement .  
● Recruitment feasibility  is an important measure of our ability to reach  individuals with BP -
PEHD. Feasibility and areas for refinement will be measured using flow data including the 
number of participants screened per month; percentage of screened participants from 
racial/ethnic minority groups; and percentage of screened participants who are 
socioeconomically disadvantaged. We will also measure the percentage of participants scre ened 
per month by [CONTACT_272973]; percentage of screened participants from  racial/ethnic 
minority groups by [CONTACT_272973]; and percentage of screened participants who are 
socioeconomically disadvantaged by [CONTACT_272973].  
 
● Enrollment feasibility  is another important measure of our ability to reach  individuals with BP -
PEHD and ensure our study enrollment processes are not providing obstructions to 
participation. Enrollment feasibility will be measured using flow data including the number of 
participants enrolled per month; percentage of enrolled participants from racial/ethnic minority 
groups; percentage of enrolled participants who are socioeconomically disadvantaged. We will 
also measure the percentage of participants exclud ed by [CONTACT_272974]; percentage of 
49 
PRP Study Protocol V5 October 2023  participants declining participation; main reasons for declined participation; average time to 
enrollment from screening visits (e.g., initial screen, baseline 1).  
 
● Intervention acceptability and credibility feasibility  is an important measure of the potential 
for the interventions’ (experimental and control) adoption and implementation ; this will be 
measured using flow data including the percentage of enrolled participants not attending any 
sessions; percentage of enrollees attending less than 6 of 9 sessions; percentage satisfied with 
interventions; and percentage reporting participation in home practice. We will also measure 
the percentage of enrolled participants w ithdrawing from interventions and reasons for 
withdrawal from interventions.  
 
● Intervention fidelity feasibility  is an important measure of the ability of Community Partner 
Organizations and Community Facilitators to be able to deliver the interventions as planned  and 
adopt them over the long term . This will be measured by [CONTACT_272975]; percentage of intervention activities across intervention 
programs not performed by [CONTACT_272976]; and frequency of intervention activities not performed 
by [CONTACT_272976] . 
● Data collection feasibility as well as the usability and functionality of our data collection systems 
are critical measures of our ability to assess the effectiveness and potential implementation of 
the interventions in the future R33 Randomized Trial. Dat a collection feasibility will be assessed 
by [CONTACT_272977] 2 assessment; the percentage of missing 
variables by [CONTACT_272978]; reasons for missed assessments; and average duration 
of assessments (see also Tab le 6, Schedule of Assessments).  
 
 
14.[ADDRESS_333599] of health 
disparities. Community Stakeholder and Study Participant views and opi[INVESTIGATOR_272913].  
Data collection methods will include surveys, interviews, focus groups, field notes , and flow data (e.g., 
screening and enrollment rates, etc.). The assessment schedule is  summarized in Table 6 and Table 9.   
14.2.1  PRIMARY EFFECTIVENESS OUTCOME   
 
For R33 Aim 1 , we will evaluate the effectiveness the Partners4Pain and Keys to Wellbeing interventions 
using self -report surveys at 2, 4 and 6 months , measuring  the primary outcome.   
The primary outcome is pain intensity and interference with life enjoyment and general activity as 
measured by [CONTACT_272979], Enjoyment of Life and General Activity (PEG) scale. The PEG is a brief three item 
scale derived from the Brief Pain Inventory that measures average pain intensity,  interference with 
enjoyment of life, and interference with general activity in the past week. Each item is measured on a 0 
(no pain/does not interfere) to 10 numeric rating scale (pain as bad as you can imagine/completely 
interferes). The overall PEG scor e provides a single measure of pain intensity and interference and is the 
average of the individual item scores with a potential range of 0 -10. The PEG has been shown to be a 
50 
PRP Study Protocol V5 October 2023  reliable and valid measure in chronic pain populations with responsiveness that is similar  to or better 
than  other commonly used pain measures.103-105 
14.2.2  SECONDARY EFFECTIVENESS OUTCOMES  
For R33 Aim 1, we will evaluate the effectiveness the Partners4Pain and Keys to Wellbeing interventions 
using self -report surveys at  2, 4 and 6 months , measuring  secondary outcome s. 
Secondary outcome measures include a range of measures consistent with the Biopsychosocial Model of 
Pain and are recommended common data elements from the HEAL initiatives core pain domains ; in 
addition , we have included important  PROMIS based measures with demonstrated reliability and 
validity in chronic pain populations.106 
• Pain impact and frequency  over the past 3 months measured using the Graded Chronic Pain 
Scale -Revis ed (GCPS -R).107 
• Physical function using the PROMIS 6 -item short form v2.0 which measures difficulty doing 
household activities and agreement with statements on health limitations in physical activities 
on a 1 to 5 scale.108,109  
• Sleep disturbance and duration using the PROMIS [ADDRESS_333600] month 
will also be obtained.  
• Participation in social roles and activities using the PROMIS 4 -item short form v2.0 which 
measures frequency of trouble doing activities for leisure, work, or with fami ly or friends on a 1 
to 5 scale.108,109 
• Anxiety will be measured using the Generalized Anxiety Disorder -2 survey (GAD -2) which 
includes 2 questions that are summed for a total score that can range from 0 to 6 .110 
• Depression will be measured using the Patient Health Questionnaire -2 (PHQ -2) which includes 2 
questions that are summed for a total score that can range from 0 to 6.110  
• Substance use will be assessed using the Tobacco, Alcohol, Prescription medications, and other 
Substance (TAPS) survey.111 The TAPS is comprised of an initial 4 -item screen for substance use 
that may lead to further assessment with substance specific surveys when indicated based on 
the initial 4 -item screen.  
• Pain catastrophizing will be assessed using the 6 -item short form of  the Pain Catastrophizing 
Scale.112  
• Self-efficacy for managing chronic conditions will be assessed using the PROMIS 4 -item short 
forms for 1) managing daily activities; 2) managing symptoms; 3) managing emotions; and 4) 
managing social interactions.113 
• Interoceptive Awareness will be measured using the Multidimensional Assessment of 
Interoceptive Awareness survey instrument (V2) using the 1) noticing; 2) attention regulation; 3) 
emotional awareness; an d 4) self -regulation subscales.114 
• Satisfaction with various domains of life (e.g., education, work, family life) will be assessed using 
the PROMIS 13 -item domain spe cific life satisfaction measure.115 
• Self-reported use of CIH self -management strategies, medications (over -the-counter and 
prescription medications - including opi[INVESTIGATOR_2438]), and health care (MRIs, injections, hospi[INVESTIGATOR_602], 
surgeries, provider visits) for back or neck pain will be measured.  
• Participants will be asked to report potential side effects by [CONTACT_215410] a list generated from 
previous studies of pain self -management programs and known potential risks of exercise and 
mindfulness interventions  (R33A T009110, NH170001, R34AT011209 ).  
51 
PRP Study Protocol V5 October 2023  • Satisfaction with the interventions will be assessed using a question that has participants rate 
their overall satisfaction ranging from completely satisfied to completely dissatisfied.106  
• Overall improvement will be assessed with the Patient Global Impression of Change (PGIC) 
which has participants rate their overall change from very much worse to very much 
improved.[ADDRESS_333601] of health disparity related factors on the effectiveness  of 
Partners4Pain intervention for primary and secondary outcomes described above through subgroup 
analyses which account for the potential relationships and complexities between disparity factors. See 
Section 15.4.2.  
14.2.3  IMPLEMENTATION & DISPARITY MITIGATING OUTCOMES  
 
For R33 Aim 3, we will assess and describe  views of factors that could facilitate implementation and 
mitigate disparities to prepare for the long -term translation of the intervention to community partner 
organizations within and beyond the trial. We will use mixed methods quality improvement data 
collection of Study Participant and Community Stakeholder views and relevant flow data.  
Study Participants will be asked to complete mixed methods surveys collected querying:  
• Views on barriers/facilitators to reach and participation  
• Perceived effectiveness of the interventions  
• Their satisfaction with and use of specific program activities  
• The extent to which they felt the program met their capability, opportunity , and motivational 
(COM) needs72  
• Their views of the intervention’s overall affordability, practicality, effectiveness, acceptability, 
safety, and equity (APEASE , which is part of the COM model)  
• The ability of the study team to create a supportive environment and develop relational 
alliances that fostered norms of inclusion and cultural sensitivity.80,93,116 -120 This includes a 
measure detailing perceived discrimination in healthcare that will be adapted to assess 
perceived discrimination within the study.101  
 
Community Stakeholders will also participate in a mixed methods evaluation (e.g., via interviews, focus 
groups, field notes) of their views of the intervention ’s APEASE features, the nature and quality of the 
researcher -community partnership , and other domains that emerge as important for sustainability and 
translation.121  
 
Flow data related to the implementation and disparity mitigating outcomes include:  
• Number, proportion, and representative characteristics of Study Participants; reasons for 
participation or not by [CONTACT_272980]  
• Number, proportion, and representative characteristics of Community Partner Organizations; 
reasons for participation  
• Number, proportion, and representative characteristics of Community Facilitators; reasons for 
participation  
 
15 STATISTICAL CONSIDERATIONS  
 
52 
PRP Study Protocol V5 October 2023  15.1 HYPOTHESES  
 
Phase I (R61): No hypotheses have been formulated for the R61 phase of the project given the focus on 
quality improvement and feasibility.  
 
Phase II (R33):   
Aim 1 Hypothesis : The Partners4Pain program will be more effective in reducing the primary outcome of 
pain intensity and interference, in addition to secondary outcomes relative to the Keys to Wellbeing 
program (active control).  
 
Aim 2 Hypothesis :  Through sub -group analyses accounting for complex relationships between disparity 
factors and multi -level evaluation of community stakeholders, we will gain insights into the program’s 
ability to mitigate disparities (e.g., by [CONTACT_272981], opp ortunity , and motivational (COM) 
barriers, as well as obstacles related to affordability, practicality, effectiveness, acceptability, safety , and 
equity (APEASE)).  
 
15.[ADDRESS_333602] found approximately 15 -20 
individuals per group  sufficient for informing the feasibility of larger, randomized clinical trials.118,119 We 
anticipate needing to consent approximately 60 to 80 participants to enroll 30 to 60 individuals into the 
trial.  
15.2.2  R33 RANDOMIZED HYBRID EFFECTIVENESS -IMPLEMENTATION TRIAL  
 
Our sample size for the R33 Randomized Hybrid Effectiveness -Implementation Trial is based on findings 
from the literature on the PEG instrument (our primary outcome measure), including data on 
responsiveness and variability .122,[ADDRESS_333603] 80% power to detect a group difference of 
approximately one unit or 10 percentage points on the PEG (0 -10 scale) based on the mean of the 2, 4, 
and [ADDRESS_333604] of sample size and group treatment factors (class size and number of classes) on 
power and detectable group difference. We used data on back pain intensity from the active control 
intervention (Keys to Wellbeing) in our team’s rec ent trial of physical activity in older adults 
(R33AT00911 ) to inform intra -class correlation. We generated normally distributed longitudinal 
measurements from the [ADDRESS_333605] error of 2.5 units .122,123 The mean response was a 
function of normally distributed individual - and class -level random effects (with variances chosen to 
achieve the above correlations) as well as a constant fixed effect of treatment at the 2 -, 4-, and 6 -month 
time points. The mean PEG during follow -up was compared between treatment groups using a linear 
mixed model with fixed effects for treatment and baseline PEG and random effects for individual and 
class. We carried out simulations across a number of scenarios with class sizes ra nging from 10 to 16 
participants and a total sample size of 300. In all scenarios, our planned sample size yielded greater than 
53 
PRP Study Protocol V5 October 2023  80% power for a treatment effect of approximately 0.9 units (0 -10 scale) , corresponding to a 
standardized between group effect size (mean difference/SD) of 0.36, which we regard as a clinically 
meaningful difference for pain intensity and interference, and is consistent with recommendations in 
the literature .124,125 To account for up to 20% loss to follow up, we plan to enroll a total of 376 
participants.  
15.3 POPULATIONS FOR ANALYSES & GENERAL APPROACH  (R33)  
 
The primary analysis for the R33 Randomized Hybrid Effectiveness -Implementation Trial will use an 
intent -to-treat (ITT) approach126 with all enrolled subjects included in the analysis. Per -protocol analysis 
including only participants compliant with study protocols will be conducted as a secondary analysis. 
Secondary analyses are exploratory and will not be corrected for multiple comp arisons. We will use 
hierarchical linear mixed model regression analyses to account for repeated measures within trial 
participants (the unit of randomization) in addition to the clustering of individuals within classes when 
receiving the experimental or c ontrol interventions.127 Missing data analyses will be informed by [CONTACT_272982] (data missing at random) and 
sensitivity analyses using pattern mixture models (data not missing at random), if appropriate.128,129 This 
approach has been applied in previous trials by [CONTACT_272983].130 
 
15.4 DATA ANALYSES  
 
15.4.1  R61 P HASE  
 
Aims 1 & 2:  Mixed method assessment will be conducted. Quantitative data will be analyzed using 
descriptive statistics when appropriate. For the qualitative analysis, experienced members of the study 
team will apply rapid deductive, directed content analytic methods o f individual and group interviews in 
real-time, audio -recordings of interviews, and text from open -ended surveys.  The coding structure and 
operational definitions will be guided by [CONTACT_1758]’s conceptual models131,[ADDRESS_333606] appropriate.  
 
In addition to using rapid qualitative approaches,132 we may also apply traditional qualitative methods 
when more nuanced information would be helpful. In these instances, we will use semi -structured 
interview guides for individual stakeholder interviews and focus groups which will be recorded and 
transcribe d verbatim. Teams of 2 -3 will perform in -depth, directed content analyses of the transcripts 
applying a codeboo k in NVivo qualitative software.136,137  We will use deductive approaches aligned with 
the study’s models and frameworks, as well as inductive thematic coding to document other important 
information that falls outside the coding structure. Representative quotations will be identified; when 
54 
PRP Study Protocol V5 October 2023  useful (e.g., to gain insight as to theme importance) we will also quantify themes by [CONTACT_272984], and presented descriptively  as frequencies.136,137   
 
Aim 3:  Mixed me thod analyses will be conducted.136  Quantitative data will be presented using 
descriptive statistics (e.g. means, percentages). No between group statistical comparisons are planned 
for the R61 Randomized Pi[INVESTIGATOR_272914]. Qualitative 
data will be analyzed using the methods described above for Aims 1 and 2.  
 
15.4.2  R33 R ANDOMIZED HYBRID EFFECTIVENESS -IMPLEMENTATION TRIAL  
 
Primary Analysis  
For the primary analysis , we will use mean PEG during follow -up (at 2, 4, and 6 months) as the outcome. 
The effect of treatment will be assessed using a hierarchical linear mixed model with fixed effects for 
treatment and baseline PEG and random effects for individual and class. I n addition, we will test for 
evidence of an interaction between time and treatment by [CONTACT_6486] a mixed model with an interaction 
between the treatment group indicator and follow -up time (viewed as a categorical random variable) 
and using a likelihood ratio test to assess whether the interaction terms are jointly significant. The 
results of this analysis will inform the interpretation of the primary analysis and guide secondary 
analyses. Analyses will be carried out using the statistical software R.  
 
Secondary Analyses  
Responder Analyses:  We will derive responder categories for our primary outcome of pain intensity and 
interference (PEG) at 2, 4, and 6 months corresponding to reductions from baseline of 30% (minimal 
improvement), 50% (moderate improvement), 75% and 100% (substantial improv ement). Then, we will 
fit proportional odds models to assess the effect of treatment on the probability of falling into each of 
these categories. In addition, we will conduct cumulative responder analyses to assess the proportion of 
resp onders for all possible levels of pain intensity and interference reduction (0 to 100% reduction).138 
 
Secondary Outcomes:  Secondary numerical outcome measures (e.g., self -efficacy, life satisfaction, 
physical functioning) will be analyzed similarly to the primary PEG outcome. Generalized linear mixed 
models will be used for binary and count outcomes.  
 
Longitudinal Analyses:  Systematic reviews and meta -analyses of interventions for chronic pain and 
chronic back pain commonly use short -, medium -, and long -term treatment effects for analysis. 
Therefore, in addition to the analyses of primary and secondary outcomes which provide  a measure of 
cumulative burden over the six -month study period, we will conduct longitudinal analyses with time 
coded as a categorical variable to quantify group differences in primary and secondary outcomes at 2, 4, 
and 6 months. Di fferences in numerical outcomes will be assessed using linear mixed models as 
described above. Differences in categorical outcomes (e.g., Graded Chronic Pain Scale, health care use) 
will be assessed using multi -level mixed effects generalized linear models . 
 
Effect Heterogeneity Analyses:  While it remains important to estimate the overall (mean) effect of an 
intervention, analyses of intervention studies have increasingly focused on characterizing how 
population subgroups experience differential treatment effects.139-141 Here, we will employ modern 
statistical machine learning methods (including some co -developed by [CONTACT_3252] -I Wolfson142) to describe how 
disparity factors (i.e. race, ethnicity, income, wealth, education, health care access) interact to influence 
how responsive individuals are to treatment. These flexible methods combining matching techniques 
[ADDRESS_333607] heterogeneity, and (in the 
presence of heterogeneity) also yield simple classification rules that partition the population according 
to their expected treatment effect. In previous work, we have successfully applied these techniques to 
randomized trials with fewer participants (n=180) than we will have in this study (n=376) so we 
anticipate that we will have an adequate sample size to achieve meaningful results. For these an alyses, 
we will use a limited set of outcomes (e.g., PEG, self -efficacy) at 2, 4, and [ADDRESS_333608]. All analyses are exploratory and will not be corrected for multiple comparisons.  
 
Mediation Analyses:  In addition to characterizing how treatment effects vary across individuals, we will 
also explore the potential mechanisms driving these treatment effects via mediation analysis. 
Specifically, we will apply established methods143 to characterize the proportion of treatment effect for 
changes in pain intensity and interference at months 4 and 6 that can be explained by [CONTACT_272985] -
efficacy, interoceptive awareness, and domain -specific life satisfaction measured in prior months.  
Mediation models will be estimated using the mediation  package in R .144 Further, we will apply 
decomposition methods145 to understand whether the relationship between treatment effects and self -
efficacy/life satisfaction is driven by [CONTACT_272986], moderation, or moderated mediation.  
 
Comparisons to Back Pain Populations with Low Health Disparities:  To assess the impact of 
Partners4Pain on mitigating disparities in pain self -management, we will compare findings to results 
from studies assessing self -management programs for chronic back pain with low PEHD representation, 
including studies from the HEA L initiative.67,[ADDRESS_333609] heterogeneity, and mediating variables. Where 
possible, we will combine individual -level data (from previous studies conducted by [CONTACT_2296]) to 
formally test differences across studies.  
 
Implementation and Disparity Mitigating Outcome Analyses:  Qualitative measures will be analyzed 
using methods described previously (see R61 Aims 1 & 2 ). Quantitative measures will be summarized 
and compared between treatment groups using two -sample t -tests (for continuous measures) and chi -
square tests (for categorical measures). Exploratory analyses will employ regression and decision tree 
models to in vestigate the impact of disparity factors (i.e., race, ethnicity, income, wealth, education, 
health care access) on measures of program implementation.   
 
16 REGULATORY, ETHICAL, & STUDY OVERSIGHT  
 
16.1 INFORMED CONSENT  
 
16.1.1  CONSENT & OTHER INFORMATIONAL DOCUMENTS  
 
Community Stakeholder  Information Sheet  
Community Stakeholders (see Table 4) will be provided with an informational sheet prior to sharing their 
views and opi[INVESTIGATOR_6153]. The information sheet details the names of the researchers, an explanation of what 
the community stakeholders will be expected to do and any risks associated with their involvement, and 
contact [CONTACT_272987].  
 
56 
PRP Study Protocol V5 October 2023  Informed Consent Form  (Study Participants)  
The consent form will include, but is not limited to, the following: information regarding the study 
purpose and research design, study procedures, potential risks and benefits, alternatives to 
participation, voluntary nature of participation, privacy and confidentiality, research -related injury, 
disclosure of new information regarding participation, and who to contact [CONTACT_272988]. Contact [CONTACT_272989](s) will also be provided. Participants, 
study s taff, and an impartial witness, as needed, will sign and date the consent form.  
 
Changes to the Informed Consent Form  
In the event the informed consent form changes, following necessary IRB approvals, study staff will 
meet with the PI [INVESTIGATOR_272915]. If existing study participants need to be informed of specific changes in the risks or 
benefits of study participation, an addendum consent will be used. This addendum will be used to, for 
example, inform enrolled participants about significant new findings that may have a bearing on their 
willingness to continue participation in the study. The addendum consent will be given to the participant 
at a study visit , emailed,  or mailed to the participant's home.  
 
16.1.2  CONSENT PROCEDURES & DOCUMENTATION  
 
Consent & Human Subjects Training  
All research staff obtaining informed consent are required to undergo project specific human subjects 
training that addresses the essential components to the informed consent process. Staff responsible for 
consenting participants will be documented in the study’s Delegation of Authority Log and in Ethos. In 
addition, staff will complete human subjects training in accordance with the UMN’s human subjects and 
HIPAA training requirements.   
 
This procedure establishes the process to obtain informed consent from participants. The process begins 
when an individual identifies as a potential candidate for the study and will continue throughout the 
duration of the study. The process ends when a par ticipant declines consent to participate (e.g., prior to 
signing the consent, withdrawing consent) or when study completion occurs. Participants must 
demonstrate the ability to autonomously provide written or electronic consent. A Legally Authorized 
Repres entative (LAR) will not be used. The Principal Investigators are responsible for ensuring these 
procedures are carried out.  
 
Potential participants will consent at 3 different time points: during a brief initial screening survey and at 
each of the two baseline screening appointments.  
 
Initial Screening Survey/Pre -Baseline Screening Visit  
Interested individuals are initially screened using a web -based screening survey that can be completed 
independently online or over the phone with study staff. An overview of the study will be provided 
during the web -screen, and electronic consent secured prior to collecting preliminary information on 
eligibility (e.g., age, presence of chronic back or neck pain). Following the web -based screening, 
potential participants will be sent an informational video describing the study in more detail and will be 
contact[CONTACT_272990] (e.g., purpose of the study, 
interventions, time commitment) and schedule the first baseline screening appointment.  
 
[ADDRESS_333610] their decision 
to participate. None are anticipated; see Conflict of Interest Policy if a change in circumstance occurs. 
Study staff will review the consent form wit h the participants, section by [CONTACT_68979]. This may be done one -
on-one or in a group setting with other potential participants. Following review of the consent form, 
participants will be invited to ask questions one -on-one with study staff in a private and qu iet space. 
Research staff will assess comprehension and understanding of information presented in the consent 
form using a series of open -ended questions (e.g., study purpose, interventions, risks). Participants will 
be encouraged to discuss taking part in  the research study with family members, friends and/or 
healthcare providers, as appropriate. Participants are encouraged to think about study participation and 
will not be coerced or pressured into deciding to participate before they are ready. Written or  electronic 
consent will be obtained from each study candidate. Only individuals who demonstrate comprehension 
will be considered eligible to participate. If the participant cannot read, an impartial witness can be 
used. The impartial witness must:  
• Be present during the entire consent discussion to attest to the adequacy of the consent process 
and to the participant's voluntary consent. The witness must be present during the entire 
consent conversation, not just for signing the document(s).  
• The witness may be a family member, friend, caregiver etc. The witness may not be a person 
involved in the design, conduct, or reporting of the research study.  
 
All participants will be given a copy of the signed consent form for their personal records. Original signed 
paper consent forms will be secured in the respective participant' s research file. Signed e -consent forms 
will be maintained in REDCap.  
 
Baseline 2 Screening Visit  
At the second baseline screening visit, research staff will review the study purpose and procedures (e.g., 
study visits, data collection) and confirm continued consent to participate.  
 
To complete the informed consent process at the end of study participation, study staff will inform the 
subject when their participation has ended and will document the discussion in the study record.  
 
16.2 STUDY DISCONTINUATION & CLOSURE  
 
The study may be temporarily suspended  or prematurely closed if there is sufficient reasonable cause. 
Written notification, documenting the reason for study suspension or termination, will be provided to 
study participants, investigators and study collaborators, funding agency, and regulatory authorities, 
including the UMN IRB, by [CONTACT_272991]. In the event of any type of closure, the PIs, or designee, 
will promptly inform ongoing study participants, the IRB, and sponsor/funding agency and provide the 
reason(s) for the termination or tem porary suspension.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
58 
PRP Study Protocol V5 October 2023  • Insufficient compliance of study staff to the protocol (i.e., significant protocol violations)  
• Data that are not sufficiently complete and/or evaluable  
• Major difficulties with study recruitment or retention  
• Natural disaster, public health crisis  
  
The study may resume once concerns about safety, protocol compliance, and data quality are addressed 
and satisfy regulatory bodies (e.g., funding agency, IRB, IMC).   
  
STUDY CLOSURE  
  
The Principal Investigators, or their designee, have the responsibility of informing the IRB, and other 
regulatory bodies, when a protocol has been completed. A protocol is considered to be open and active 
until the investigator has notified the IRB the st udy has been completed.  
 
Study Close Out Procedures are as follows:  
• Confirm a signed ICF is on file for each participant  
• All CRFs for each participant are complete or closed; all other data entry is complete  
• Status of all outstanding data edits, queries , or missing data is known and there is a timeline for 
their resolution  
• Procedures for locking the database are complete or in progress  
• All regulatory and other pertinent study documents for the protocol are current, complete , and 
on file (e.g., IRB approvals, consent documents, current CRFs)  
• Inform IRB of study closure status or identify plans to this, per IRB reporting requirements  
• Notify monitoring committee of study closure status  
• Update clinicaltrials.gov  
• Update Study Closure Status  
• Post the study Informed Consent Form to clinicaltrials.gov  
• Study results will be submitted to clinicaltrials.gov no later than 12 months after the primary 
completion date)  
• Following publication of study findings, de -identified and non -traceable data generated by [CONTACT_272992] -appropriate repositories in consultation with the HEAL Data 
Stewardship Group to ensure the data is accessible via the HEAL In itiative Data Ecosystem.  
 
16.3 CONFIDENTIALITY & PRIVACY  
 
Participant confidentiality and privacy is strictly held in trust by [CONTACT_3486], their 
staff, the IMC, and the funding agency. This confidentiality is extended to the data being collected as 
part of this study. Data that could be used to identify a specific study participant will be held in strict 
confidence within the research team.  
 
Authorized representatives of the funding agency, representatives of the Institutional Review Board 
(IRB), and other regulatory agencies may inspect all documents and records required to be maintained 
by [CONTACT_38453].   
 
The study participant’s contact [CONTACT_9168]. At 
the end of the study, all records will continue to be kept in a secure location for as long a period as 
[ADDRESS_333611] protected; HIPAA compliant 
databases stored on secure servers also operated  by [CONTACT_272993] (HST). The 
servers are in a physically secure location on campus and are backed up nightly, with the backups stored 
in accordance with the HST. Hard -copy participant research files, with identifiable information, will be 
secured in a locked file cabinet, in a locked office, with no public access at the University of Minnesota 
(UMN). Further, study participants will be assigned a unique ID number . This ID number will be used in 
lieu of using identifiable information whenever possible. Identifiable information will be accessible to 
study -related personnel who have met the UMN’s training requirements for the Responsible Conduct of 
Research, HIPAA , and data security.  
 
Routine communication with study participants regarding scheduling and reminders for study visits will 
occur by [CONTACT_61529]. Authorization for email communication regarding scheduling and reminders 
for study visits will be obtained from participants.  
 
All published reports will be of summary nature and no individual subjects will be identified beyond the 
investigative staff involved in the project.  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
not include the participant’s contact [CONTACT_1290]. Rather, individual participants and their 
research data will be identified by a unique study identification number.  
 
Certificate of Confidentiality  
To further protect the privacy of study participants, the Secretary, Health and Human Services (HHS), 
has issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, behavioral, 
clinical or other human subjects research funded w holly or in part by [CONTACT_48160]. Recipi[INVESTIGATOR_272916] (see https://humansubjects.nih.gov/coc/index ). It 
is the NIH policy that investigators and others who have access to research records will not disclose 
identifying information except when the participant consents or in certain instances when federal, state, 
or local law or regulation requires disclo sure. NIH expects investigators to inform research participants 
of the protections and the limits to protections provided by a Certificate issued by [CONTACT_17355].  
16.4 KEY ROLES & STUDY GOVERNANCE  
 
The structure and organization of the study team is summarized  in Table 10  and is based on the 
investigators’  previous work successfully conducting complex milestone driven projects.  
 
Members of the study team represent a professionally diverse group of individuals from scientific and 
community settings and are at various stages of their research and professional careers. They have been 
strategically brought together based on their skills and experience which will enhance the likelihood of 
the project’s success.  
 
Due to the project’s complexity, there are two Principal Investigators (PIs).  
 
60 
PRP Study Protocol V5 October 2023  Table 10. Key Roles and Study Governance  
Study Committee/Team/Hub  Roles & Responsibilities  
Steering Committee  
(Comprised of PIs and Co -Is, 
Community Partner 
Organization Leadership 
Members as Co -I Consultants)  • Provide guidance to the PIs related to the overall scientific agenda, 
decision making, monitoring of study progress and the dissemination and 
implementation plan  
• Facilitates relationships between researchers and Community Partner 
Organizations  
Management Team  
(Comprised of Co-I Hub Leads , 
PIs, Project Coordinators ) • Oversees study development and implementation  
• Supports and monitors Individual Team Hub Progress  
• Develops/maintains Overall Study Team Charter  
• Maintains regular communication with Community Partne r Organizations  
regarding study status and collaboration  
• Develops and routinely reviews protocol  
• Conducts regular review of study progress, timelines, budget, payment of 
consultants, etc.  
Project Coordination Hub  
(Comprised of Project 
Coordinators, PIs)  • Coordinates research activities across hubs  
• Standardizes processes for priorities work -flow management using project 
management tools (e.g., ClickUp)  
• Identifies and brings attention to barriers obstructing timeline completion 
of milestones, time sensitive issues  
• Assembles and maintains entire study MOP; initiates timely review of MOP 
sections  
• Maintains Project Coordination MOP Sections  
Regulatory Hub * 
 • Coordinates, develops, maintains, ensures compliance regarding:  
• IRB submissions  
• Protocol  
• AE/UPI[INVESTIGATOR_272917]  
• Regulatory Binder  
• Delegation of Authority Logs  
• Coordinates, trains staff and ensures compliance re: Informed Consent 
Activities  
• Coordinates, ensures documentation and compliance of Human Subjects 
Training of study staff  
• Coordinates meetings, preparation of reports and responses related to 
Independent Monitoring Committee  
• Maintains timely reporting on Clinicaltrials. gov  
• Maintains Regulatory MOP Sections  
Data Collection and 
Management Hub*  
 • Coordinates development of study CRFs  
• Develops and maintains study databases/management systems (REDCap)  
• Coordinates randomization system  
• Trains staff in data collection/management activities  
• Stores and manages all study related data  
• Prepares data for data analysis  
• Oversees quality assurance and quality control of data collection and data 
management  
• Prepares monitoring reports for internal and external reporting purposes  
• Maintains Data Collection and Management  MOP Sections  
Intervention Hub*  • Develops the intervention curricula for experimental and control  
61 
PRP Study Protocol V5 October 2023  • Designs, develops, and produces intervention assets; seeks input from 
Community Stakeholders with the assistance of the Data Management 
Hub 
• Works with the Delivery Platforms, Technology Hub to produce website 
related content  
• Hires, trains, and managements Community Facilitators  
• Designs, develops intervention training materials for Study Staff and 
Community Facilitators  
• Designs, develops, and implements intervention CRFs, fidelity assessments 
in coordination with the Data Management Hub  
• Maintains Intervention MOP Sections  
Delivery Platforms, Technology 
Hub*  • Assesses and makes recommendations for delivery platforms and 
technology to support participant facing activities  
• Develops and trains staff in the use of associated delivery platforms and 
technology  
• Coordinates the design, development and maintenance of the study 
related website Partners4Pain.org  
• Maintains Delivery Platforms, Technology MOP Sections  
Community Engagement and 
Recruitment Hub*  • Develops and implements the recruitment plan  
• Develops and implements the engagement plan  
• Coordinates convening of Community Advisory Team  
• Works with the Data Management Hub to coordinate Community 
Stakeholder Quality Improvement Data Collection  
• Maintains Community Engagement and Recruitment Hub MOP Sections  
Communications, Public 
Relations Hub*  • Develops and implements communications and public relations plans  
• Designs, develops, and produces communication assets (e.g., brand kit, 
press releases, newsletters, etc.)  
• Works with the Delivery Platforms, Technology Hub to produce website 
related content  
• Maintains Communications, Public Relations Hub MOP Sections  
Participant Coordination Hub*  • Coordinates activities with Data Collection/Management and Community 
Engagement Hubs  
• Responsible for overseeing the implementation of all activities at a 
participant level; includes:  
• Reminder emails (sessions, follow up)  
• Scheduling visits  
• Monitoring communication systems  
• Troubleshooting and assisting participants as needed  
• Maintains Participant Coordination Hub MOP Sections  
62 
PRP Study Protocol V5 October 2023  Community Advisory Team  
(Comprised of Community 
Members and Leadership from 
Community Partner 
Organizations Serving in 
Consultant Roles)  
 
 
 
 
 
 
 
 
 
 
 Work s in partnership with researchers to  
• Advise researchers on how to overcome barriers to engaging diverse 
populations in research participation  
• Connect researchers to other community organizations and community 
leaders to encourage community member participation in a range of 
research -related activities  
• Co-facilitate community talks and other conversations  
• Contribute to study conceptualization, design, development, 
implementation, results interpretation, and dissemination  
• Co-create and co -develop culturally sensitive research processes and 
materials  
• Contribute to decisions regarding new and ongoing projects upon 
researcher request  
• Expand reach to involve more communities in the research process  
• Disseminate recruitment materials through routine communication 
channels  
Community Champi[INVESTIGATOR_5458]  
(Comprised of individuals from 
varied organizational domains 
including health care 
professionals, faith -based 
leaders, charitable 
organizations, neighborhood 
associations, senior 
communities, etc.)  • Disseminate recruitment materials through routine communication 
channels  
*Hubs (with the exception of  the Project Coordination Hub) are comprised of at least one PI, at least one Co -I 
with subject matter expertise, and at least one Project Coordinator  
MOP=Manual of Operations  
 
16.[ADDRESS_333612].  
 
16.6 CLINICAL MONITORING  
 
Study monitoring will be conducted internally by [CONTACT_272994]; that the reported trial data are accurate, complete, and verifiable; 
and the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
International Council on Harmonization Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s). Self -monitoring activities are described in Section 16.7,  Quality Assurance and Quality 
Control.  
63 
PRP Study Protocol V5 October 2023   
16.7 QUALITY ASSURANCE & QUALITY CONTROL  
 
We will perform internal quality management of study conduct, data collection, documentation, and 
completion.  
 
Quality assurance and control procedures will be implemented as follows:  
 
Research staff will undergo project -specific training in informed consent, screening and enrollment 
procedures, data collection, safety assessment, and adverse event protocols prior to study enrollment. 
Study intervention facilitators will undergo project -specific training in screening and enrollment 
procedures, their respective interventions, and safety assessment and adverse event protocols prior to 
study enrollment. Certification by a principal investigator (or designee) requires adherence to standard 
operating procedures outlined in the manual of operations. Training and certification will be logged.  
 
Informed consent — Study staff will review both the documentation of the consenting process as well 
as completed consent documents for enrolled participants.  This review will evaluate compliance with 
GCP, accuracy, and completeness.  Feedback will be provided to the study t eam to ensure proper 
consenting procedures are followed .  
 
Outcome data collection — The primary method of data collection for participant self -reported 
outcomes will be direct electronic entry through a survey interface with REDCap. Logic rules specifying 
the type and range of acceptable responses will be programmed into REDCap. Partici pants will receive 
an error message if they enter an invalid response. The PIs will review reports on data capture and 
quality on a monthly basis. Missing data reporting and other customized reports will be developed in 
order to fac ilitate efficient workflow and high -quality data capture. Data collection instrument specific 
follow -up rates will be tabulated and reviewed during meetings between the PIs and study staff. 
Additional training will be provided as needed based on the findin gs. 
 
Intervention Fidelity — Consistent delivery of the study interventions will be monitored throughout the 
intervention phase of the study. Procedures for ensuring fidelity of intervention delivery are described in 
Section 11.4.   
 
Protocol Deviations  — The study team will review protocol deviations on an ongoing basis and will 
implement corrective actions when the quantity or nature of deviations are deemed to be at a level of 
concern.  
 
16.8 DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645]  
 
16.8.1  DATA COLLECTION & MANAGEMENT RESPONSIBILITIES  
 
Data collection and accurate documentation are the responsibility of the study staff under the 
supervision of the investigators. All source documents will be reviewed by [CONTACT_272995], who will ensure that they are accurate and comple te. Unanticipated problems and adverse 
events will be reviewed by [CONTACT_1719].   
 
[ADDRESS_333613] servers provide a stable, 
secure, well -maintained, and high -capacity data storage environment, and both REDCap and MySQL are 
widely used, powerful, reliable, well -supported systems. Access to the study's data in REDCap will be 
restricted to the m embers of the study team by [CONTACT_125698]. The database incorporates an 
electronic audit trail to show change(s) to data after original entry including the date/time and user 
making the change. Electronic communication with outside collaborators wi ll involve only non -
identifiable information.  
 
Source Document Protection  
Electronic source documents will be stored on a password protected computers supported and 
maintained by [CONTACT_272996]. Participant ID numbers will be used to protect participants’ confidentiality. 
All paper source documents will be stored in a locked file cabinet, in a locked office at the University of 
Minnesota with no public access.  
16.8.2  STUDY RECORDS RETENTION  
 
Study documents will be retained for a minimum of 3 years from the date of Federal Financial Report (FFR) 
submission. Documents may be retained for a longer period, if required by [CONTACT_427].  
 
16.9 PROTOCOL DEVIATIONS  
 
This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol, 
International Council on Harmoni sation Good Clinical Practice (ICH GCP), or Manual of Procedures 
(MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, 
or the study site staff. As a result of deviations, corrective actions will be developed b y the study team 
and implemented promptly, as required. It is the responsibility of investigators and research staff to 
follo w the written protocol approved by [CONTACT_1201].  
65 
PRP Study Protocol V5 October 2023   
Protocol deviations include, but are not limited to the following:  
• Failure to keep IRB approval up to date  
• Implementing protocol modifications without obtaining prospective IRB approval  
• Conducting research during a lapse in IRB approval  
• Enrolling more subjects than what is approved in the protocol  
• Performing research procedures outside the protocol specified window  
• Failure on the part of any individual involved in research review or oversight to abide by 
[CONTACT_115155], or the University of Minnesota IRB policies  
• Randomization of an ineligible participant; not -adhering to inclusion/exclusion criteria  
• Failure to obtain Informed Consent or altering from the informed consent process as described 
in the IRB approved protocol, including obtaining consent using an outdated consent form  
• Failure to report an SAE, Breach of Confidentiality, Unanticipated Problem  
• Failure to report an event that requires expedited reporting to the IRB (e.g., unexpected death, 
participant becomes incarcerated)  
• Wrong intervention administered to a participant  
 
Documenting and Reporting Requirements  
All protocol deviations, violations and research failures will be documented in REDCap by [CONTACT_464]. 
Deviations, violations, and research failures that are also SAEs, UPI[INVESTIGATOR_16104], or result in harm to the 
participant may have different, or additional, repor ting requirements. See Sections 13.5 to 13.6  of this 
study protocol for more information.  
 
Protocol deviations and violations will be reported to regulatory agencies as required (e.g., IMC reports 
per reporting requirements outlined in the DSMP and/or Charter; per the UMN IRB and funding agency 
requirements).  
16.10  PUBLICATION & DATA SHARING POLICY  
 
This study will be conducted in accordance with the following publication and data sharing policies and 
regulations:  
 
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the di gital archive PubMed Central upon acceptance for 
publication. Electronic copi[INVESTIGATOR_272918] a 
journal in PubMed Central with proper metadata to be made discoverable and accessible upon 
publication. P ublications will be made publicly available immediately without any embargo period and 
will be published under the Creative Commons Attribution 4.0 Generic License (CC BY 4.0) or an 
equivalent license or otherwise dedicated to the public domain (e.g., Crea tive Commons public domain 
tool, CC0).  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As 
such, this trial will be registered at Clinica lTrials.gov, and results information from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -
reviewed journals. Data generated by [CONTACT_272997] -appropriate reposit ories in 
66 
PRP Study Protocol V5 October 2023  consultation with the HEAL Data Stewardship Group to ensure the data is accessible via the HEAL 
Initiative Data Ecosystem. To the extent feasible, underlying primary data will be shared simultaneously 
with publications and made immediately accessible throu gh release under the CC BY 4.0 or an 
equivalent license or otherwise dedicated to the public domain (e.g., Creative Commons public domain 
tool, CC0). Considerations for ensuring confidentiality of these shared data are described in Section 
16.[ADDRESS_333614] policies that 
require the timely disclosure of financial and business interests relating to the researcher’s University 
responsibilities and expertise. Disclosure of th ese interests is required annually and within 30 days of a 
“change in circumstances” using the Report of External Professional Activities (REPA). Current REPA 
reports are maintained for study staff (paid faculty, P&A employees and other individuals designa ted by 
a senior UMN leader or designate) with study regulatory documents. Covered individuals must complete 
the University’s conflict of interest course when filing the REPA for the first time, and every four years 
thereafter. University investigators must  disclose all reportable conflicts to the University’s Office of 
Institutional Compliance (OIC).  
 
The existence of financial and/or business interests related to the research study will be disclosed in the 
New Study and Continuing Review forms in ETHOS for all study personnel. Any conflict not previously 
disclosed to the IRB will be reported via the Re portable New Information SmartForm in ETHOS. The 
investigators will also submit a modification in ETHOS to address any revisions to the study if required.  
 
The following strategies may be employed when COIs or potential COIs are identified. The strategies 
below are organized from minimal to more restrictive management and are not an exhaustive list. 
Management plans will be submitted to the IRB for approval a nd other regulatory bodies will be notified 
per their respective policies (e.g., IMC, NIH).  
• Disclose (if legally permissible) the conflict in the informed consent form and in any publications 
or presentations related to the research  
• Restrict the conflicted person’s access to identifiable data  
• Restrict the conflicted person’s ability to determine eligibility status of prospective participants.  
• Restrict the conflicted person from obtaining informed consent  
• Restrict the conflicted person from adjudicating adverse events, serious adverse events and/or 
unanticipated problems  
• Restrict the conflicted person’s participation in data analysis and interpretation  
67 
PRP Study Protocol V5 October 2023  • Remove conflicted person from involvement in the conduct of the study. This is a last resort 
consideration that may require regulatory approval (e.g, sponsor approval, steering committee 
approval).  
 
16.12  FUTURE USE OF DATA  
 
Measures Taken to Ensure Confidentiality of Data Shared per the NIH Data Sharing Policies  
It is NIH policy that the results and accomplishments of the activities that it funds should be made 
available to the public (see  https://grants.nih.gov/policy/sharing.htm ). The PIs will ensure all 
mechanisms used to share data will include proper plans and safeguards for the protection of privacy, 
confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de -
identified and will not be  traceable to a specific study participant). The study is funded by [CONTACT_18121]’s 
Helpi[INVESTIGATOR_272919] -term (HEAL) initiative and will comply with the HEAL Initiative’s Public 
Access and Data Sharing Policy ( https://heal.nih.gov/about/public -access -data ). This includes submitting 
de-identified and non -traceable data generated by [CONTACT_272998] -appropriate repositories in 
consultation with the HEAL Data Stewardship Group to ensure the data is accessible via the HEAL 
Initiative Data Ecosystem. Plans for sharing data for future use will be disclosed to study participants 
during informed consent.   
 
17 REFERENCES  
 
1. Bronfort G, Evans R, Anderson AV, Svendsen KH, Bracha Y, Grimm RH. Spi[INVESTIGATOR_203577], medication, or home exercise with advice for acute and subacute neck 
pain: a randomized trial. Ann Intern Med. 2012;156(1.1):1 -10. 
2. Bronfort G, Hondras MA, Schulz CA, Evans RL, Long CR, Grimm R. Spi[INVESTIGATOR_272920] -related leg pain: a trial 
with adaptive allocation. Ann Intern Med. 2014;161(6):381 -391.  
3. Bronfort G, Maiers MJ, Evans RL, et al. Supervised exercise, spi[INVESTIGATOR_197974], and 
home exercise for chronic low back pain: a randomized clinical trial. Spi[INVESTIGATOR_050] J. 
2011;11(7):585 -598.  
4. Evans R, Bronfort G, Schulz C, et al. Supervised exercise with and without spi[INVESTIGATOR_272921]: a 
randomized controlled trial. Spi[INVESTIGATOR_050]. 2012;37(11):903 -914.  
5. Evans R, Haas M, Schulz C, Leininger B, Hanson L, Bronfort G. Spi[INVESTIGATOR_272922]: a randomized trial. Pain. 2018;159(7):1297 -
1307.  
6. Maiers M, Bronfort G, Evans R, et al. Spi[INVESTIGATOR_272923]. Spi[INVESTIGATOR_050] J. 2014;14(9):1879 -1889.  
7. Maiers M, Hartvigsen J, Evans R, et al. Short or long -term treatment of spi[INVESTIGATOR_272924]. Arthritis Care Res (Hoboken). 2018.  
8. Schulz C, Evans R, Maiers M, Schulz K, Leininger B, Bronfort G. Spi[INVESTIGATOR_272925]: a randomized clinical 
trial. Chiropractic & Manual Therapi[INVESTIGATOR_014]. 2019;27(1):21.  
68 
PRP Study Protocol V5 October 2023  9. Burgess DJ, Evans R, Allen KD, et al. Learning to Apply Mindfulness to Pain (LAMP): 
Design for a Pragmatic Clinical Trial of Two Mindfulness -Based Interventions for Chronic 
Pain. Pain Medicine. 2020;21(Supplement_2):S29 -S36.  
10. Bastian LA, Cohen SP, Katsovich L, et al. Stakeholder Engagement in Pragmatic Clinical 
Trials: Emphasizing Relationships to Improve Pain Management Delivery and Outcomes. 
Pain Medicine. 2020;21(Supplement_2):S13 -S20.  
11. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in 
[LOCATION_002] adults: results of an Internet -based survey. The journal of pain : official 
journal of the American Pain Society. 2010;11(11):1230 -1239.  
12. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990 -2010: burden of 
diseases, injuries, and risk factors. JAMA. 2013;310(6):[ADDRESS_333615] 
Chronic Pain in the [LOCATION_002]. The Journal of Pain. 2019;20(2):146 -160.  
14. Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the 
[LOCATION_002]. PAIN. 2021.  
15. Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with 
disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. 
Annals of Translational Medicine. 2020;8(6):299.  
16. Safiri S, Kolahi A -A, Hoy D, et al. Global, regional, and national burden of neck pain in the 
general population, 1990 -2017: systematic analysis of the Global Burden of Disease 
Study 2017. Bmj. 2020;368:m791.  
17. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back 
pain. Arthritis and rheumatism. 2012;64(6):2028 -2037.  
18. Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988;318(5):[ADDRESS_333616] Res 
Clin Rheumatol. 2010;24(6):[ADDRESS_333617] M, et al. Chronic spi[INVESTIGATOR_272926] -mental comorbidity 
in the [LOCATION_002]: results from the national comorbidity survey replication. Pain. 
2005;113(3):331 -339.  
21. Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back 
pain. Arch Intern Med. 2009;169(3):251 -258.  
22. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming 
Prevention, Care, Education, and Research.  Washington (DC): National Academies Press; 
2011.  
23. Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by [CONTACT_272999], 1996 -2016. Jama. 2020;323(9):863 -884.  
24. Pi[INVESTIGATOR_35807] T, Kent P, Bronfort G, Loisel P, Pransky G, Hartvigsen J. Twenty -five years with the 
biopsychosocial model of low back pain -is it time to celebrate? A report from the 
twelfth international forum for primary care research on low back pain. Spi[INVESTIGATOR_050]. 
2013;38(24):2118 -2123.  
25. Hush JM. Low back pain: it is time to embrace complexity. PAIN. 2020;161(10):2248 -
2251.  
69 
PRP Study Protocol V5 October 2023  26. Carey TS, Freburger JK, Holmes GM, et al. Race, care seeking, and utilization for chronic 
back and neck pain: population perspectives. The journal of pain : official journal of the 
American Pain Society. 2010;11(4):[ADDRESS_333618] to go: practice patterns and 
evidence in chronic low back pain care. Spi[INVESTIGATOR_050]. 2009;34(7):718 -724.  
28. Stevans JM, Delitto A, Khoja SS, et al. Risk Factors Associated With Transition From 
Acute to Chronic Low Back Pain in US Patients Seeking Primary Care. JAMA Network 
Open. 2021;4(2):e2037371 -e2037371.  
29. Mardian AS, Hanson ER, Villarroel L, et al. Flippi[INVESTIGATOR_272927]: A 
Sociopsychobiological Approach to High -Value Chronic Pain Care. Pain Med. 2020.  
30. Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: 
evidence, challenges, and promising directions. Lancet. 2018;391([ZIP_CODE]):2368 -2383.  
31. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 
1980;137(5):535 -544.  
32. Manchikanti L, Pampati V, Hirsch JA. Retrospective cohort study of usage patterns of 
epi[INVESTIGATOR_272928] -for-service Medicare population from 
2000 to 2014. BMJ Open. 2016;6(12):e013042.  
33. Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating chronic back pain: time to back 
off? Journal of the American Board of Family Medicine : JABFM. 2009;22(1):62 -68. 
34. Reuben DB, AA HA, Ashikaga T, et al. National Institutes of Health Pathways to 
Prevention Workshop: The Role of Opi[INVESTIGATOR_272929]. Ann Intern 
Med. 2015.  
35. Raad M, Donaldson CJ, El Dafrawy MH, et al. Trends in isolated lumbar spi[INVESTIGATOR_272930] 40 -64 years, 2010 -2014. J Neurosurg Spi[INVESTIGATOR_050]. 
2018;29(2):169 -175.  
36. Lee SW, Patel J, Kim SY, Miranda -Comas G, Herrera J, Bartels MN. Use of Opi[INVESTIGATOR_272931]. Am J Phys 
Med Rehabil. 2019;98(8):e97 -e98.  
37. Jami M, Marrache M, Puvanesarajah V, Raad M, Prasad N, Jain A. Treatment of Neck 
Pain with Opi[INVESTIGATOR_272932]: Trends and Geographic Variation. Pain 
Med. 2020.  
38. Mansell G, Hall A, Toomey E. Behaviour change and self -management interventions in 
persistent low back pain. Best Pract Res Clin Rheumatol. 2016;30(6):994 -1002.  
39. Carnes D, Homer KE, Miles CL, et al. Effective delivery styles and content for self -
management interventions for chronic musculoskeletal pain: a systematic literature 
review. Clin J Pain. 2012;28(4):344 -354.  
40. Milani CJ, Rundell SD, Jarvik JG, et al. Associations of Race and Ethnicity With Patient -
Reported Outcomes and Health Care Utilization Among Older Adults Initiating a New 
Epi[INVESTIGATOR_272933]. Spi[INVESTIGATOR_050]. 2018;43(14):1007 -1017.  
41. Friedman J, Kim D, Schneberk T, et al. Assessment of Racial/Ethnic and Income 
Disparities in the Prescription of Opi[INVESTIGATOR_272934]. 
JAMA Intern Med. 2019;179(4):469 -476.  
70 
PRP Study Protocol V5 October 2023  42. Singhal A, Tien YY, Hsia RY. Racial -Ethnic Disparities in Opi[INVESTIGATOR_272935]. 
PLoS One. 2016;11(8):e0159224.  
43. Ringwalt C, Roberts AW, Gugelmann H, Skinner AC. Racial Disparities Across Provider 
Specialties in Opi[INVESTIGATOR_272936]. Pain Medicine. 2015;16(4):633 -640.  
44. Ghoshal M, Shapi[INVESTIGATOR_2152] H, Todd K, Schatman ME. Chronic Noncancer Pain Management and 
Systemic Racism: Time to Move Toward Equal Care Standards. J Pain Res. 2020;13:2825 -
2836.  
45. Ghildayal N, Johnson PJ, Evans RL, Kreitzer MJ. Complementary and Alternative 
Medicine Use in the US Adult Low Back Pain Population. Glob Adv Health Med. 
2016;5(1):69 -78. 
46. Braveman PA, Cubbin C, Egerter S, et al. Socioeconomic status in health research: one 
size does not fit all. Jama. 2005;294(22):2879 -2888.  
47. Meghani SH, Chittams J. Controlling for Socioeconomic Status in Pain Disparities 
Research: All -Else-Equal Analysis When "All Else" Is Not Equal. Pain Med. 
2015;16(12):2222 -2225.  
48. Karran E, Grant A, Moseley L. Low back pain and the social determinants of health: a 
systematic review and narrative synthesis. Pain. 2020;161.  
49. Janevic MR, McLaughlin SJ, Heapy AA, Thacker C, Pi[INVESTIGATOR_74182]. Racial and Socioeconomic 
Disparities in Disabling Chronic Pain: Findings From the Health and Retirement Study. 
The journal of pain : official journal of the American Pain Society. 2017;18(12):[ADDRESS_333619] Chronic 
Pain Among Adults - [LOCATION_002], 2016. MMWR Morb Mortal Wkly Rep. 
2018;67(36):1001 -1006.  
51. Ashworth J, Konstantinou K, Dunn KM. Prognostic factors in non -surgically treated 
sciatica: a systematic review. BMC Musculoskelet Disord. 2011;12:208.  
52. Hasenbring M, Marienfeld G, Kuhlendahl D, Soyka D. Risk factors of chronicity in lumbar 
disc patients. A prospective investigation of biologic, psychologic, and social predictors 
of therapy outcome. Spi[INVESTIGATOR_050]. 1994;19(24):[ADDRESS_333620] 
time incidence sciatica: a systematic review. Physiother Res Int. 2014;19(2):65 -78. 
54. Chou R, Shekelle P. Will this patient develop persistent disabling low back pain? JAMA. 
2010;303(13):1295 -1302.  
55. Karos K, Williams ACC, Meulders A, Vlaeyen JWS. Pain as a threat to the social self: a 
motivational account. Pain. 2018;159(9):1690 -1695.  
56. Sturgeon JA, Zautra AJ. Social pain and physical pain: shared paths to resilience. Pain 
Manag. 2016;6(1):63 -74. 
57. Foster NE, Delitto A. Embedding psychosocial perspectives within clinical management 
of low back pain: integration of psychosocially informed management principles into 
physical therapi[INVESTIGATOR_39402] --challenges and opportunities. Phys Ther. 2011;91(5):790 -
803.  
71 
PRP Study Protocol V5 October 2023  58. Bair MJ, Matthias MS, Nyland KA, et al. Barriers and facilitators to chronic pain self -
management: a qualitative study of primary care patients with comorbid 
musculoskeletal pain and depression. Pain Med. 2009;10(7):1280 -1290.  
59. Upshur CC, Bacigalupe G, Luckmann R. “They Don't Want Anything to Do with You”: 
Patient Views of Primary Care Management of Chronic Pain. Pain Med. 
2010;11(12):1791 -1798.  
60. Pi[INVESTIGATOR_272937], Ferreira ML, Refshauge K, et al. Symptoms of depression as a prognostic 
factor for low back pain: a systematic review. Spi[INVESTIGATOR_050] J. 2016;16(1):105 -116.  
61. Tegner H, Frederiksen P, Esbensen BA, Juhl C. Neurophysiological Pain Education for 
Patients With Chronic Low Back Pain: A Systematic Review and Meta -Analysis. Clin J 
Pain. 2018;34(8):778 -786.  
62. Wood L, Hendrick PA. A systematic review and meta -analysis of pain neuroscience 
education for chronic low back pain: Short -and long -term outcomes of pain and 
disability. Eur J Pain. 2019;23(2):234 -249.  
63. Skelly AC, Chou R, Dettori JR, et al. AHRQ Comparative Effectiveness Reviews. In: 
Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review 
Update.  Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.  
64. Morone NE, Greco CM, Moore CG, et al. A Mind -Body Program for Older Adults With 
Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2016;176(3):329 -
337.  
65. Cherkin DC, Sherman KJ, Turner JA. Mindfulness -Based Stress Reduction vs Cognitive 
Behavioral Therapy for Chronic Low Back Pain --Reply. Jama. 2016;316(6):663 -664.  
66. Meng XG, Yue SW. Efficacy of aerobic exercise for treatment of chronic low back pain: a 
meta -analysis. Am J Phys Med Rehabil. 2015;94(5):358 -365.  
67. Du S, Hu L, Dong J, et al. Self -management program for chronic low back pain: A 
systematic review and meta -analysis. Patient Education and Counseling. 2017;100(1):37 -
49. 
68. van Erp RMA, Huijnen IPJ, Jakobs MLG, Kleijnen J, Smeets R. Effectiveness of Primary 
Care Interventions Using a Biopsychosocial Approach in Chronic Low Back Pain: A 
Systematic Review. Pain Pract. 2019;19(2):[ADDRESS_333621] -delivered cognitive -behavioural 
interventions are effective for low back pain, but can they be replicated in clinical 
practice? A systematic review. Disabil Rehabil. 2018;40(1):1 -9. 
70. CDC. Self Management Education: Learn More, Feel Better — Managing Chronic Pain. 
https://www.cdc.gov/learnmorefeelbetter/programs/chronic -pain.htm . Accessed Dec 6, 
2021.  
71. Foster G, Taylor SJC, Eldridge S, Ramsay J, Griffiths CJ. Self‐management education 
programmes by [CONTACT_136016]. Cochrane Database of 
Systematic Reviews. 2007(4).  
72. Michie S AL, West R. The Behaviour Change Wheel: A Guide to Designing Interventions.  
London: Silverback Publishing; 2014.  
73. Hardman R, Begg S, Spelten E. What impact do chronic disease self -management 
support interventions have on health inequity gaps related to socioeconomic status: a 
systematic review. BMC Health Services Research. 2020;20(1):150.  
[ADDRESS_333622] in need: a scopi[INVESTIGATOR_272938]. Arthritis Care Res (Hoboken). 2011;63(1):39 -52. 
75. Waldron EM, Hong S, Moskowitz JT, Burnett -Zeigler I. A Systematic Review of the 
Demographic Characteristics of Participants in US -Based Randomized Controlled Trials 
of Mindfulness -Based Interventions. Mindfulness. 2018;9(6):1671 -1692.  
76. Rhee TG, Evans RL, McAlpi[INVESTIGATOR_272939], Johnson PJ. Racial/Ethnic Differences in the Use of 
Complementary and Alternative Medicine in US Adults With Moderate Mental Distress. 
Journal of primary care & community health. 2017;8(2):43 -54. 
77. Whedon JM, Song Y. Racial disparities in the use of chiropractic care under Medicare. 
Altern Ther Health Med. 2012;18(6):20 -26. 
78. Nguyen M, Ugarte C, Fuller I, Haas G, Portenoy RK. Access to care for chronic pain: racial 
and ethnic differences. The journal of pain : official journal of the American Pain Society. 
2005;6(5):301 -314.  
79. Macinko J, Upchurch DM. Factors Associated with the Use of Meditation, U.S. Adults 
2017. J Altern Complement Med. 2019;25(9):[ADDRESS_333623] Framework: a model for advancing 
behavioral medicine science and practice to foster health equity. J Behav Med. 
2017;40(1):[ADDRESS_333624] M, Schulz AJ, Israel BA, Rice K, Martenies SE, Markarian E. A conceptual 
framework for evaluating health equity promotion within community -based 
participatory research partnerships. Evaluation and program planning. 2018;70:25 -34. 
82. Heller C, Balls -Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial 
enrollment of underrepresented populations: a systematic review. Contemp Clin Trials. 
2014;39(2):169 -182.  
83. Vojta D, Koehler TB, Longjohn M, Lever JA, Caputo NF. A Coordinated National Model 
for Diabetes Prevention: Linking Health Systems to an Evidence -Based Community 
Program. American Journal of Preventive Medicine. 2013;44(4, Supplement 4):S301 -
S306.  
84. Saper R. Integrative Medicine and Health Disparities. Glob Adv Health Med. 2016;5(1):5 -
8. 
85. Gardiner P, Lestoquoy AS, Negash NL, et al. Lessons Learned and Strategies for 
Recruitment of Diverse, Low -income Patients into an Integrative Medical Group Visit 
Clinical Trial. EXPLORE. 2019;15(3):215 -221.  
86. George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority 
research participation among African Americans, Latinos, Asian Americans, and Pacific 
Islanders. American journal of public health. 2014;104(2):e16 -31. 
87. Nicholson LM, Schwirian PM, Groner JA. Recruitment and retention strategies in clinical 
studies with low -income and minority populations: Progress from 2004 -2014. Contemp 
Clin Trials. 2015;45(Pt A):34 -40. 
88. Otado J, Kwagyan J, Edwards D, Ukaegbu A, Rockcliffe F, Osafo N. Culturally Competent 
Strategies for Recruitment and Retention of African American Populations into Clinical 
Trials. Clin Transl Sci. 2015;8(5):[ADDRESS_333625] S, Occa A, Peng W, Awonuga O, Morgan SE. Community -Based 
Participatory Research (CBPR) to Enhance Participation of Racial/Ethnic Minorities in 
Clinical Trials: A 10 -Year Systematic Review. Health Commun. 2021:[ADDRESS_333626], Brikho B, et al. Community -Academic Partnerships: A Systematic 
Review of the State of the Literature and Recommendations for Future Research. 
Milbank Q. 2016;94(1):163 -214.  
91. Craig KD, Holmes C, Hudspi[CONTACT_3433] M, et al. Pain in persons who are marginalized by [CONTACT_170343]. Pain. 2020;161(2):261 -265.  
92. Baig AA, Lopez FY, DeMeester RH, Jia JL, Peek ME, Vela MB. Addressing Barriers to 
Shared Decision Making Among Latino LGBTQ Patients and Healthcare Providers in 
Clinical Settings. LGBT Health. 2016;3(5):335 -341.  
93. Yoshikawa K, Brady B, Perry MA, Devan H. Sociocultural factors influencing 
physiotherapy management in culturally and linguistically diverse people with persistent 
pain: a scopi[INVESTIGATOR_17971]. Physiotherapy. 2020;107:292 -305.  
94. Wallerstein N, Oetzel JG, Sanchez -Youngman S, et al. Engage for Equity: A Long -Term 
Study of Community -Based Participatory Research and Community -Engaged Research 
Practices and Outcomes. Health Education & Behavior. 2020;47(3):380 -390.  
95. Glasgow RE, Harden SM, Gaglio B, et al. Use of the RE -AIM Framework: Translating 
Research to Practice with Novel Applications and Emerging Directions.  Frontiers Media 
SA; 2021.  
96. Lehman BJ, David DM, Gruber JA. Rethinking the biopsychosocial model of health: 
Understanding health as a dynamic system. Social and Personality Psychology Compass. 
2017;11(8).  
97. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template 
for intervention description and replication (TIDieR) checklist and guide. Bmj. 
2014;348(mar07 3):g1687 -g1687.  
98. Atkins L, Michie S. Designing interventions to change eating behaviours. Proc Nutr Soc. 
2015;74(2):164 -170.  
99. Shelton RC, Chambers DA, Glasgow RE. An Extension of RE -AIM to Enhance 
Sustainability: Addressing Dynamic Context and Promoting Health Equity Over Time. 
Frontiers in public health. 2020;8:134 -134.  
100.  Michie S, Wood CE, Johnston M, Abraham C, Francis JJ, Hardeman W. Behaviour change 
techniques: the development and evaluation of a taxonomic method for reporting and 
describing behaviour change interventions (a suite of five studies involving consensu s 
methods, randomised controlled trials and analysis of qualitative data). Health 
technology assessment. 2015;19(99):[ADDRESS_333627], Yan Y, Jackson JS, Anderson NB. Racial Differences in Physical and Mental 
Health: Socio -economic Status, Stress and Discrimination. J Health Psychol. 
1997;2(3):335 -351.  
102.  Vaughn LM, Whetstone C, Boards A, Busch MD, Magnusson M, Määttä S. Partnering 
with insiders: A review of peer models across community -engaged research, education 
and social care. Health & social care in the community. 2018;26(6):769 -786.  
74 
PRP Study Protocol V5 October 2023  103.  Kean J, Monahan PO, Kroenke K, et al. Comparative Responsiveness of the PROMIS Pain 
Interference Short Forms, Brief Pain Inventory, PEG, and SF -36 Bodily Pain Subscale. 
Med Care. 2016;54(4):[ADDRESS_333628] of Opi[INVESTIGATOR_272940] -
Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: 
The SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872 -882.  
105.  Chen CX, Kroenke K, Stump T, et al. Comparative Responsiveness of the PROMIS Pain 
Interference Short Forms With Legacy Pain Measures: Results From Three Randomized 
Clinical Trials. The journal of pain : official journal of the American Pain Society. 
2019;20(6):664 -675.  
106.  Wandner LD, Domenichiello AF, Beierlein J, et al. NIH's Helpi[INVESTIGATOR_200608] -
term(SM) Initiative (NIH HEAL Initiative) Clinical Pain Management Common Data 
Element Program. The journal of pain : official journal of the American Pain Society. 
2021.  
107.  Von Korff M, DeBar LL, Krebs EE, Kerns RD, Deyo RA, Keefe FJ. Graded chronic pain scale 
revised: mild, bothersome, and high -impact chronic pain. Pain. 2020;161(3):[ADDRESS_333629], 
physical function, and social function demonstrated clinical validity across a range of 
chronic conditions. Journal of clinical epi[INVESTIGATOR_623]. 2016;73:89 -102.  
109.  Deyo RA, Katrina R, Buckley DI, et al. Performance of a Patient Reported Outcomes 
Measurement Information System (PROMIS) Short Form in Older Adults with Chronic 
Musculoskeletal Pain. Pain Med. 2016;17(2):314 -324.  
110.  Kroenke K, Spi[INVESTIGATOR_4280], Williams JB, Lowe B. An ultra -brief screening scale for anxiety and 
depression: the PHQ -4. Psychosomatics. 2009;50(6):613 -621.  
111.  McNeely J, Wu LT, Subramaniam G, et al. Performance of the Tobacco, Alcohol, 
Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use 
Screening in Primary Care Patients. Ann Intern Med. 2016;165(10):690 -699.  
112.  McWilliams LA, Kowal J, Wilson KG. Development and evaluation of short forms of the 
Pain Catastrophizing Scale and the Pain Self -efficacy Questionnaire. Eur J Pain. 
2015;19(9):1342 -1349.  
113.  Gruber -Baldini AL, Velozo C, Romero S, Shulman LM. Validation of the PROMIS((R)) 
measures of self -efficacy for managing chronic conditions. Qual Life Res. 
2017;26(7):1915 -1924.  
114.  Mehling WE, Acree M, Stewart A, Silas J, Jones A. The Multidimensional Assessment of 
Interoceptive Awareness, Version 2 (MAIA -2). PLoS One. 2018;13(12):e0208034.  
115.  Salsman JM, Lai JS, Hendrie HC, et al. Assessing psychological well -being: self -report 
instruments for the NIH Toolbox. Qual Life Res. 2014;23(1):[ADDRESS_333630] competence or group cohesion -contributes to 
reduction of psychological distress in group -based mindfulness -based cognitive therapy 
for cancer patients. Clin Psychol Psychother. 2019;26(3):309 -318.  
117.  Babatunde F, MacDermid J, MacIntyre N. Characteristics of therapeutic alliance in 
musculoskeletal physiotherapy and occupational therapy practice: a scopi[INVESTIGATOR_272941]. BMC Health Serv Res. 2017;17(1):375.  
[ADDRESS_333631]. The 
therapeutic alliance between clinicians and patients predicts outcome in chronic low 
back pain. Phys Ther. 2013;93(4):470 -478.  
119.  Goldberg SB, Davis JM, Hoyt WT. The role of therapeutic alliance in mindfulness 
interventions: therapeutic alliance in mindfulness training for smokers. J Clin Psychol. 
2013;69(9):[ADDRESS_333632] an influence on pain and physical 
functioning in patients with chronic musculoskeletal pain; a systematic review. Journal 
of Compassionate Health Care. 2016;3(1):1.  
121.  Israel BA, Lachance L, Coombe CM, et al. Measurement Approaches to Partnership 
Success: Theory and Methods for Measuring Success in Long -Standing Community -
Based Participatory Research Partnerships. Progress in community health partnerships : 
research, education, and action. 2020;14(1):129 -140.  
122.  Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a 
three -item scale assessing pain intensity and interference. J Gen Intern Med. 
2009;24(6):733 -738.  
123.  Krebs EE, Bair MJ, Damush TM, Tu W, Wu J, Kroenke K. Comparative responsiveness of 
pain outcome measures among primary care patients with musculoskeletal pain. Med 
Care. 2010;48(11):[ADDRESS_333633] SA, Faurot K, et al. The design and methods of the OPTIMUM study: 
A multisite pragmatic randomized clinical trial of a telehealth group mindfulness 
program for persons with chronic low back pain. Contemp Clin Trials. 2021;109:106545.  
125.  Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of 
treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The 
journal of pain : official journal of the American Pain Society. 2008;9(2):105 -121.  
126.  Fisher L, Dixon D, Herson J, Frankowski R, Hearron M, Peace K. Statistical issues in drug 
research and development. Statistical issues in drug research and development. 1990.  
127.  Andridge RR, Shoben AB, Muller KE, Murray DM. Analytic methods for individually 
randomized group treatment trials and group -randomized trials when subjects belong 
to multiple groups. Statistics in medicine. 2014;33(13):[ADDRESS_333634] MG. Missing data in randomised controlled trials: a practical 
guide. In: Health Technology Assessment Methodology Programme; 2007.  
129.  Bunouf P, Molenberghs G. Implementation of pattern -mixture models in randomized 
clinical trials. Pharm Stat. 2016;15(6):494 -506.  
130.  Liao JM, Stack CB. Annals Understanding Clinical Research: Implications of Missing Data 
Due to Dropout. Ann Intern Med. 2017;166(8):[ADDRESS_333635] MA, et al. Rapid versus traditional qualitative 
analysis using the Consolidated Framework for Implementation Research (CFIR). 
Implementation Science. 2021;16(1):67.  
132.  Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health 
Res. 2005;15(9):1277 -1288.  
133.  Holtrop JS, Estabrooks PA, Gaglio B, et al. Understanding and applying the RE -AIM 
framework: Clarifications and resources. Journal of Clinical and Translational Science. 
2021;5(1):e126.  
[ADDRESS_333636] Implementation 
and Sustainability Model (PRISM) to qualitatively assess multilevel contextual factors to 
help plan, implement, evaluate, and disseminate health services programs. Translational 
Behavioral Medicine. 2019;9(6):1002 -1011.  
135.  Palinkas LA, Zatzick D. Rapid Assessment Procedure Informed Clinical Ethnography 
(RAPI[INVESTIGATOR_21785]) in Pragmatic Clinical Trials of Mental Health Services Implementation: Methods 
and Applied Case Study. Adm Policy Ment Health. 2019;46(2):255 -270.  
136.  Creswell JW. Research Design: Qualitative, Quantitative, and Mixed Methods 
Approaches.  SAGE Publications; 2013.  
137.  Creswell J, Plano -Clark V. Designing and Conducting Mixed Methods Research.  Vol 2nd 
ed. Thousand Oaks, CA: Sage Publications; 2011.  
138.  Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis 
graph to present pain data over a range of cut -off points: making clinical trial data more 
understandable. J Pain Symptom Manage. 2006;31(4):[ADDRESS_333637] Heterogeneity (PATH) Statement. Ann Intern Med. 2020;172(1):[ADDRESS_333638] heterogeneity in randomized program 
evaluation. The Annals of Applied Statistics. 2013;7(1):[ADDRESS_333639] 
heterogeneity in clinical trials using subpopulations of events: STEPP. Clin Trials. 
2016;13(2):[ADDRESS_333640] heterogeneity of a randomized treatment using conditional inference trees. 
Statistical methods in medical research. 2021:9622802211052831.  
143.  Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. 
Psychological methods. 2010;15(4):309 -334.  
144.  Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal 
Mediation Analysis. Journal of Statistical Software. 2014;59(5):1 - 38. 
145.  VanderWeele TJ. A unification of mediation and interaction: a [ADDRESS_333641] decomposition. 
Epi[INVESTIGATOR_623]. 2014;25(5):749 -761.  
 